<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">56793</article-id><article-id pub-id-type="doi">10.7554/eLife.56793</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>TMEM79/MATTRIN defines a pathway for Frizzled regulation and is required for <italic>Xenopus embryogenesis</italic></article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-180549"><name><surname>Chen</surname><given-names>Maorong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3744-8864</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-180550"><name><surname>Amado</surname><given-names>Nathalia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0243-7196</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-180551"><name><surname>Tan</surname><given-names>Jieqiong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/><xref ref-type="fn" rid="pa1">‡</xref></contrib><contrib contrib-type="author" id="author-180552"><name><surname>Reis</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-180553"><name><surname>Ge</surname><given-names>Mengxu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-180554"><name><surname>Abreu</surname><given-names>Jose Garcia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-19547"><name><surname>He</surname><given-names>Xi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8093-7981</contrib-id><email>Xi.He@childrens.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution>F. M. Kirby Neurobiology Center, Boston Children’s Hospital, Department of Neurology, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro</institution><addr-line><named-content content-type="city">Rio de Janeiro</named-content></addr-line><country>Brazil</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nusse</surname><given-names>Roel</given-names></name><role>Reviewing Editor</role><aff><institution>Stanford University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Wolberger</surname><given-names>Cynthia</given-names></name><role>Senior Editor</role><aff><institution>Johns Hopkins University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>‡</label><p>Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China</p></fn><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>14</day><month>09</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e56793</elocation-id><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-09-11"><day>11</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Chen et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Chen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-56793-v2.pdf"/><abstract><p>Wnt signaling through the Frizzled (FZD) family of serpentine receptors is essential for embryogenesis and homeostasis, and stringent control of the FZD protein level is critical for stem cell regulation. Through CRISPR/Cas9 genome-wide screening in human cells, we identified TMEM79/MATTRIN, an orphan multi-span transmembrane protein, as a specific inhibitor of Wnt/FZD signaling. TMEM79 interacts with FZD during biogenesis and promotes FZD degradation independent of ZNRF3/RNF43 ubiquitin ligases (R-spondin receptors). TMEM79 interacts with <italic>u</italic>biquitin-<italic>s</italic>pecific <italic>p</italic>rotease 8 (USP8), whose activating mutations underlie human tumorigenesis. TMEM79 specifically inhibits USP8 deubiquitination of FZD, thereby governing USP8 substrate specificity and promoting FZD degradation. Tmem79 and Usp8 genes have a pre-bilaterian origin, and Tmem79 inhibition of Usp8 and Wnt signaling is required for anterior neural development and gastrulation in <italic>Xenopus</italic> embryos. <italic>TMEM79</italic> is a predisposition gene for Atopic dermatitis, suggesting deregulation of Wnt/FZD signaling a possible cause for this most common yet enigmatic inflammatory skin disease.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>tmem79/mattrin</kwd><kwd>frizzled</kwd><kwd>WNT</kwd><kwd>USP8</kwd><kwd>neural induction</kwd><kwd>anterior-posterior (ap) patterning</kwd><kwd>Atopic dermatitis</kwd><kwd>ubiquitination</kwd><kwd>stem cells</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>Xenopus</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01GM126120</award-id><principal-award-recipient><name><surname>He</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006823</institution-id><institution>Boston Children's Hospital</institution></institution-wrap></funding-source><award-id>Boston Children's Hospital (BCH) Pilot and Translational Research Program (TRP) grants</award-id><principal-award-recipient><name><surname>He</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006823</institution-id><institution>Boston Children's Hospital</institution></institution-wrap></funding-source><award-id>BCH Intellectual and Developmental Disabilities Research Center (P30 HD-18655)</award-id><principal-award-recipient><name><surname>He</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006691</institution-id><institution>Harvard Medical School</institution></institution-wrap></funding-source><award-id>Goldenson fellowship</award-id><principal-award-recipient><name><surname>Amado</surname><given-names>Nathalia</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002822</institution-id><institution>Central South University</institution></institution-wrap></funding-source><award-id>Visiting scholarship</award-id><principal-award-recipient><name><surname>Tan</surname><given-names>Jieqiong</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003593</institution-id><institution>Conselho Nacional de Desenvolvimento Científico e Tecnológico</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Abreu</surname><given-names>Jose Garcia</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>He</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R35GM134953</award-id><principal-award-recipient><name><surname>He</surname><given-names>Xi</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Rio de Janeiro State Foundation for Science support</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Abreu</surname><given-names>Jose Garcia</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution>Chinese Scholarship Council</institution></institution-wrap></funding-source><award-id>Visiting scholarship</award-id><principal-award-recipient><name><surname>Tan</surname><given-names>Jieqiong</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>TMEM79 targets frizzled receptor for degradation through inhibiting USP8 and is required for <italic>Xenopus embryogenesis</italic>.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Signaling by the Wnt family of secreted proteins is essential for animal development and tissue homeostasis, and deregulation of Wnt signaling underlies various human diseases including cancer (<xref ref-type="bibr" rid="bib42">Nusse and Clevers, 2017</xref>; <xref ref-type="bibr" rid="bib16">Gammons and Bienz, 2018</xref>). The Frizzled (FZD) family of serpentine proteins are receptors for most or all Wnt signaling pathways, while LRP5/6 (LDL receptor-related proteins 5 and 6) are coreceptors specifically for the Wnt/β-catenin pathway, which regulates the stability/abundance of transcription co-activator β-catenin (<xref ref-type="bibr" rid="bib34">MacDonald and He, 2012</xref>). The Wnt responsiveness of a cell is stringently controlled by the FZD protein level at the plasma membrane (PM), as best illustrated by the action of R-spondin (Rspo) proteins, a family of secreted Wnt agonists that enhance Wnt signaling by stabilizing FZD at the PM (<xref ref-type="bibr" rid="bib8">Cruciat and Niehrs, 2013</xref>). Rspo acts by binding to and inhibiting two related transmembrane ubiquitin ligases for FZD, ZNRF3 and RNF43, which are Rspo receptors and frequently inactivated mutationally in cancers (<xref ref-type="bibr" rid="bib10">de Lau et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Hao et al., 2016</xref>). The Rspo/ZNRF3 or RNF43 complex, together with LGR4/5/6 (leucine-rich G-protein coupled receptor 4/5/6) co-receptors highlights a sophisticated system for governance of the FZD protein level across a broad spectrum of stem cell regulation (<xref ref-type="bibr" rid="bib10">de Lau et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Hao et al., 2016</xref>). Complementarily deubiquitinating enzymes such as ubiquitin-specific protease 8 (USP8), a member of the USP superfamily (<xref ref-type="bibr" rid="bib28">Leznicki and Kulathu, 2017</xref>), act to remove ubiquitination of FZD, thereby countering the action of ubiquitin ligases and stabilizing FZD (<xref ref-type="bibr" rid="bib39">Mukai et al., 2010</xref>) as well as other transmembrane receptors (<xref ref-type="bibr" rid="bib37">Mizuno et al., 2005</xref>; <xref ref-type="bibr" rid="bib50">Row et al., 2006</xref>; <xref ref-type="bibr" rid="bib1">Alwan and van Leeuwen, 2007</xref>; <xref ref-type="bibr" rid="bib41">Niendorf et al., 2007</xref>; <xref ref-type="bibr" rid="bib60">Xia et al., 2012</xref>). Oncogenic activation of USP8 by missense mutations or chromosomal translocation has been linked to pituitary adenoma (Cushing’s Disease) (<xref ref-type="bibr" rid="bib32">Ma et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Reincke et al., 2015</xref>) and leukemia (<xref ref-type="bibr" rid="bib22">Janssen et al., 1998</xref>), respectively, and its expression is associated with poor prognosis of lung cancer cases (<xref ref-type="bibr" rid="bib24">Kim et al., 2017</xref>), consistent with its role in stabilizing receptors for multiple growth factors. It is unknown, however, if or how the broad substrate specificity of USP8, or for that matter of other USPs (<xref ref-type="bibr" rid="bib28">Leznicki and Kulathu, 2017</xref>), is governed.</p><p>Regulation of Wnt signaling has critical roles in vertebrate embryogenesis. Most notably the dorsal Spemann-Mangold organizer of <italic>Xenopus embryos</italic> produces a plethora of secreted or membrane-bound Wnt antagonists, in addition to secreted BMP (bone morphogenetic protein) antagonists (<xref ref-type="bibr" rid="bib11">De Robertis and Kuroda, 2004</xref>; <xref ref-type="bibr" rid="bib40">Niehrs, 2004</xref>). A prevailing view is that organizer-derived BMP antagonists serve as neural inducers that neuralize the overlying native ectoderm to form anterior CNS, while Organizer-derived Wnt antagonists ensure anterior patterning and head formation (<xref ref-type="bibr" rid="bib11">De Robertis and Kuroda, 2004</xref>; <xref ref-type="bibr" rid="bib40">Niehrs, 2004</xref>). Recently Notum, a secreted Wnt antagonist/deacylase expressed in naive ectoderm was shown to be required for neuralization and anterior patterning of <italic>Xenopus</italic> embryos, revealing a previously unrecognized role of a Wnt antagonist acting within naive ectoderm as a prerequisite for CNS formation (<xref ref-type="bibr" rid="bib65">Zhang et al., 2015</xref>). This requirement appears to be distinct from the requirement for Organizer-derived BMP and Wnt antagonists and may represent a ‘double insurance’ mechanism envisioned by Spemann for explaining the robustness of induction (<xref ref-type="bibr" rid="bib55">Spemann, 1938</xref>). The role of naive ectoderm-derived Wnt antagonists in anterior patterning and neuralization remains to be further substantiated.</p><p>Here, we identify, via CRISPR/Cas9 genome-wide loss-of function screening, an orphan five-pass transmembrane protein TMEM79 (also called MATTRIN), as a specific antagonist of Wnt signaling. TMEM79 down-regulates the FZD protein level through promoting FZD ubiquitination and degradation during biogenesis. TMEM79 acts in a pathway that is independent of ZNRF3/RNF43 ubiquitin ligases via associating with USP8 and inhibits USP8 deubiquitination of FZD specifically. We show that Tmem79 is essential for <italic>Xenopus embryogenesis</italic>. Tmem79 depletion in naive ectoderm leads to anterior patterning, neuralization and neural crest defects, which are rescued by co-depletion of Usp8 or β-catenin, corroborating its molecular role in antagonizing Wnt/β-catenin signaling and underscoring critical roles of Wnt antagonists in naïve ectoderm for CNS development. Tmem79 also plays a role in FZD/planar cell polarity (PCP) signaling and regulates gastrulation movements in axial mesoderm. Our findings uncover TMEM79 as a novel antagonist of Wnt/FZD signaling and shed insights into USP regulation and vertebrate embryogenesis. Interestingly, TMEM79 is a predisposition gene for atopic dermatitis (AD) (<xref ref-type="bibr" rid="bib53">Sasaki et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Saunders et al., 2013</xref>), the most common chronic and relapsing inflammatory skin disease that affects 20% children and 5–10% adults but with poorly defined molecular etiology (<xref ref-type="bibr" rid="bib43">Oyoshi et al., 2009</xref>; <xref ref-type="bibr" rid="bib9">Dainichi et al., 2018</xref>). Our data imply that deregulation of Wnt/FZD signaling may be a possible cause of AD pathogenesis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TMEM79 is a specific antagonist of Wnt signaling</title><p>We performed genome-wide CRISPR/Cas9 loss-of-function screening in human HEK293T cells for negative components of Wnt/β-catenin signaling using an established Wnt-responsive reporter system, which drives EGFP (enhanced green fluorescence protein) expression via multimerized WREs (Wnt-responsive elements) (<xref ref-type="fig" rid="fig1">Figure 1A,B</xref>). Validating our screening strategy, top hits from two independent screens included genes encoding known Wnt pathway components, such as APC (the <italic>adenomatous polyposis coli</italic> gene product) and CK1α (casein kinase 1α), both components of the β-catenin destruction complex (<xref ref-type="bibr" rid="bib33">MacDonald et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Gammons and Bienz, 2018</xref>), as well as ZNRF3 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). RNF43 is minimally expressed in HEK293T cells (<xref ref-type="bibr" rid="bib18">Hao et al., 2012</xref>). Among top hits, we focused on <italic>TMEM79</italic>, which encodes a putative five-pass transmembrane protein of unknown biochemical nature (<xref ref-type="bibr" rid="bib53">Sasaki et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Saunders et al., 2013</xref>; <xref ref-type="fig" rid="fig1">Figure 1C,D</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Of interests, a <italic>Tmem79</italic> gene mutation in <italic>matted</italic> (<italic>Tmem79<sup>ma/ma</sup></italic>) mice causes atopic dermatitis (AD) and matted hair phenotypes, and <italic>TMEM79</italic> is a predisposition gene for AD in human (<xref ref-type="bibr" rid="bib53">Sasaki et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Saunders et al., 2013</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Identification of TMEM79 as an inhibitor of Wnt/β-catenin signaling through genome-wide loss-of-function screening using the CRISPR-Cas9 system.</title><p>(<bold>A</bold>) An outline of the screening strategy for negative components of Wnt/β-catenin signaling using a HEK293T-TOP-EGFP reporter line. (<bold>B</bold>) Representative images of the reporter cells with or without infection of the GeCKO library. GFP<sup>+</sup> cells were enriched by FACS. Scale bar, 200 µm. (<bold>C</bold>) Scatter plots showing candidate genes corresponding to sgRNAs enriched. Results of two independent screens are shown. Each dot represents a candidate gene. Y-axis: number of unique sgRNAs for each gene (six sgRNAs per gene in the GeCKO library). X-axis: sgRNA NGS (next generation sequencing) reads for each gene. (<bold>D</bold>) Schematic diagram of TMEM79 protein (predicted). Y280*, a nonsense mutation at tyrosine 280 coded by the <italic>matted</italic> allele in mice.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56793-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Evolutionary comparison of Tmem79 proteins in vertebrates, protostomes, and cnidarians.</title><p>(<bold>A</bold>) ClustalW alignment of TMEM79/Tmem79 proteins from human (<italic>Homo sapiens</italic>), chimpanzee (<italic>Pan troglodytes</italic>), rat (<italic>Rattus norvegicus</italic>), mouse (<italic>Mus musculus</italic>), chicken (<italic>Gallus gallus</italic>), frog (<italic>Xenopus laevis</italic>), zebra fish (<italic>Danio rerio</italic>), coelacanth (<italic>Latimeria chalumnae</italic>), hemicordate (<italic>Saccoglossus kowalevskii</italic>), great scallop (<italic>Pecten maximus</italic>), leech (<italic>Helobdella robusta</italic>), cauliflower coral (<italic>Pocillopora damicornis</italic>), and sea anemone (<italic>Nematostella vectensis</italic>). Black and grey represent identical and conservative amino acid residues, respectively. Note that the amino terminus before the transmembrane domain 1 (TM1) is poorly conserved and shown only partially. The predicted Tmem79 of <italic>Nematostella vectensis</italic> appears to lack the 5th transmembrane domain (TM5) that is present in other species listed. Accession numbers for the Tmem79 sequences in the alignment are listed in Materials and methods section. (<bold>B</bold>) The phylogenetic tree showing homology among Tmem79 proteins from species presented in A based on Neighbor-Joining phylogenetic methods. Distances in the cladogram are derived from amino acid substitutions. (<bold>C</bold>) Orthologous comparisons of identity of Tmem79 proteins among species listed in A using ClustalW alignment. (<bold>D</bold>) ClustalW alignment of vertebrate TMEM79/Tmem79 proteins from human, chimpanzee, rat, mouse, chicken, frog, zebra fish, and coelacanth with mouse MAPEG family members Mgst1, Mgst2, Mgst3, Flap and Ltc4s (<xref ref-type="bibr" rid="bib12">Emrick et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Saunders et al., 2013</xref>). Asterisk indicates two conserved residues within the region of limited sequence similarity corresponding to mouse Tmem79 R332 and Y339.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig1-figsupp1-v2.tif"/></fig></fig-group><p>We validated the screening result of TMEM79 via a different but complementary siRNA-mediated knockdown approach. Depletion of TMEM79 using two different siRNAs increased, with or without Wnt3a stimulation, the activity of a WNT-responsive luciferase reporter (TOP-Flash), which is driven by multimerized WREs (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). Enhancement of TOP-Flash by TMEM79 siRNAs was similar to that by siRNA depletion of ZNRF3 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), while overexpression of TMEM79 decreased Wnt3a-induced activation of TOP-Flash (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). TMEM79 knockdown or overexpression did not affect FOP-Flash, a negative control luciferase reporter that is driven by multimerized but mutated WREs and is therefore not Wnt-responsive (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). TMEM79 knockdown or overexpression also did not affect other stimuli-responsive reporters including EGF (epidermal growth factor)-induced activation of a luciferase reporter (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–D</xref>). These results highlight TMEM79 specificity for the Wnt pathway in mammalian cells. To further examine TMEM79 specificity, we tested it in <italic>Xenopus</italic> embryos using animal pole explants that are known to be responsive to multiple signaling pathways. TMEM79 blocked signaling by Wnt8, but not by FGF (fibroblast growth factor), Nodal/TGF-β (transforming growth factor-β), BMP, or Shh (Sonic Hedgehog) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), attesting TMEM79 as a specific Wnt signaling antagonist in embryos. TMEM79 did not inhibit signaling by β-catenin (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) or by a compound GSK3 inhibitor that stabilizes β-catenin (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>), thus acting upstream of the β-catenin degradation complex.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>TMEM79 is a specific inhibitor of Wnt/β-catenin signaling.</title><p>(<bold>A</bold>) siRNA depletion of TMEM79 enhances top-flash reading with or without Wnt3a. A ZNRF3 siRNA serves as a positive control. CM, conditioned medium. TOP-Flash is quantified using RLA (relative luciferase activity), with the control set as 1. (<bold>B</bold>) TMEM79 dose-dependently suppresses top-flash. FOP, a negative control luciferase reporter. EV, empty vector. Inset: immunoblot of TMEM79 proteins, with β-actin as loading control. (<bold>C</bold>) In animal pole explants of <italic>Xenopus</italic> embryos, TMEM79 inhibits expression of xnr3 induced by Wnt8 but not by β-catenin. TMEM79 does not inhibit expression of target genes (Xbra, vent2, and Gli1) induced by Nodal, FGF, BMP, or Shh, respectively. Ef1α: RT-PCR/loading control; WE, whole embryo; Uninj, uninjected embryo; -RT: no reverse transcriptase. In this and all other figures, gradient bars symbolize different doses of DNA in transfection or mRNA in embryo injection; error bars represent SEM from at least three independent experiments; *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001, ****p&lt;0.0001 are based on student’s t-tests.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56793-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>TMEM79 is a specific inhibitor for Wnt/β-catenin signaling.</title><p>(<bold>A</bold> and <bold>B</bold>) TMEM79 affects neither the cAMP/PKA pathway, assayed by a CRE (cAMP responsive element)-driven reporter, or the EGF/EGFR pathway, assayed by an SRE (serum response element)-(driven reporter). (<bold>C</bold> and <bold>D</bold>) Depletion of TMEM79 by siRNAs affects neither the CRE- or SRE-driven reporter. (<bold>E</bold>) TMEM79 inhibits the TOP-Flash reporter induced by Wnt3a but not that induced by a GSK3 inhibitor (GSK3i). (<bold>F</bold>) Relative mRNA levels of TMEM79 in HEK293 cells transfected with indicated siRNA.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56793-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>TMEM79 downregulates the FZD protein level independent of ZNRF3/RNF43</title><p>IWP-2, a compound inhibitor specific for the PORCUPINE acyl-transferase required for Wnt lipid modification and secretion (<xref ref-type="bibr" rid="bib5">Chen et al., 2009</xref>; <xref ref-type="bibr" rid="bib59">Willert and Nusse, 2012</xref>), suppressed elevated levels of both TOP-Flash and β-catenin protein caused by depletion of either TMEM79 or ZNRF3 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), suggesting that autocrine Wnt production is required for enhanced Wnt signaling upon TMEM79 depletion, similar to that by ZNRF3 depletion (<xref ref-type="bibr" rid="bib18">Hao et al., 2012</xref>). We generated <italic>TMEM79</italic> knockout (T79KO, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) HEK293T cells, which exhibited enhanced TOP-Flash comparable to that observed in <italic>ZNRF3/RNF43</italic> double knockout (ZRKO) cells (<xref ref-type="bibr" rid="bib23">Jiang et al., 2015</xref>) in the absence of exogenous Wnt stimulation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Elevated levels of phosphorylated LRP6 and phosphorylated DVL (Dishevelled), which is an FZD downstream component, were also observed in T79KO and ZRKO cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>), suggesting enhanced autocrine Wnt signaling in absence of TMEM79 or ZNRF3/RNF43. Indeed IWP-2 suppressed elevated levels of both phosphoproteins (<xref ref-type="fig" rid="fig3">Figure 3B</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). These results suggest that TMEM79, like ZNRF3, acts to down-regulate Wnt responsiveness through FZD, which controls phosphorylation of both LRP6 and DVL (<xref ref-type="bibr" rid="bib33">MacDonald et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Gammons and Bienz, 2018</xref>). The level of endogenous FZD5 proteins was indeed elevated in T79KO cells comparably as in ZRKO cells (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Thus, like ZNRF3, TMEM79 appears to down-regulate the FZD protein level. We then examined if TMEM79 and ZNRF3 act in the same pathway or different pathways for FZD down-regulation. Interestingly, TMEM79 antagonized Wnt signaling in ZRKO cells, so did ZNRF3 in T79KO cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>), indicating that TMEM79 and ZNRF3/RNF43 function independently of each other. Consistent with this notion, siRNA depletion of ZNRF3 further elevated TOP-Flash activation in T79KO cells, and so did siRNA depletion of TMEM79 in ZRKO cells (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), suggesting that TMEM79 and ZNRF3 act in parallel in FZD downregulation.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>TMEM79 down-regulates the Frizzled (FZD) protein level at the cell surface independent of ZNRF3/RNF43.</title><p>(<bold>A</bold>) Porcupine inhibitor IWP-2 abolishes Top-Flash activities induced by a TMEM79 siRNA. (<bold>B</bold>) Levels of phospho-LRP6 and phospho-DVL2 are elevated in T79KO and ZRKO cells, and are reduced/reversed by IWP-2, as detected by a phospho-LRP6 (S1490) antibody and the upper DVL2 protein band, respectively. (<bold>C</bold>) Endogenous FZD5 levels are elevated in T79KO and ZRKO cells comparably. FZD null cells (knockout of FZD1-10) (<xref ref-type="bibr" rid="bib13">Eubelen et al., 2018</xref>) serve as control for immunoblotting specificity. (<bold>D</bold>) TMEM79 and ZNRF3 inhibit Wnt signaling independent of each other. (<bold>E</bold>) siRNA depletion of ZNRF3 or TMEM79 further elevates TOP-Flash activities in T79KO or ZRKO cells. (<bold>F</bold>) Co-IP of TMEM79 (Flag-tagged) with endogenous FZD5 but not LRP6. (<bold>G</bold>) TMEM79 is co-IPed with each FZD (FZD1 to 8) but not SMO, and with FZD9 and FZD10 but not SMO (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). (<bold>H</bold>) TMEM79 reduces the surface level of FZD5 as indicated by cell surface protein biotinylation assay. Surface proteins were labeled by membrane-impermeable biotin and isolated by streptavidin agarose (strep). Either TMEM79 or ZNRF3 reduces the upper band of FZD5 (the matured and biotinylated form) in input and streptavidin-precipitates, suggesting that TMEM79 or ZNRF3 diminishes surface level of FZD5. Note surface-biotinylation of ZNRF3 but not TMEM79, indicating that TMEM79 is not at the plasma membrane. (<bold>I</bold>) TMEM79 co-IPs the immature form of FZD5. (<bold>J</bold>) FZD5-K0 is resistant to down-regulation by TMEM79 or ZNRF3.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56793-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>TMEM79 inhibits Wnt/β-catenin signaling by reducing surface level of frizzled receptor.</title><p>(<bold>A</bold>) Depletion of TMEM79 or ZNRF3 via an siRNA in HEK293T cells induces cytosolic β-catenin accumulation, which is prevented by IWP-2. (<bold>B</bold>) Genomic DNA sequencing showing indel (frame shift) mutations of <italic>TMEM79</italic> alleles in the T79KO clone picked/used. Two clones were picked and tested with indistinguishable results (data not shown). (<bold>C</bold>) Top-flash reporter is activated comparably and strongly in T79KO cells and ZRKO cells. (<bold>D</bold>) <xref ref-type="fig" rid="fig3">Figure 3B</xref> quantification. Phospho-LPR6 (pS1490) and phospho-DVL2 (the upper band) levels are measured and normalized to total LRP6 and DVL2 levels, respectively. (<bold>E</bold>) Overexpression of TMEM79 and ZNRF3 proteins in ZRKO and T79KO cells, respectively. (<bold>F</bold>) TMEM79 is co-IPed with FZD5 (positive control), FZD9, and FZD10, but not SMO (negative control). (<bold>G</bold>) Mature FZD5 (the upper band) is de-glycosylated by PNGase and converted to the lower band as un-glycosylated immature FZD5. (<bold>H</bold>) TMEM79 co-IPs preferentially the lower band of FZD9, likely the immature form, and reduces the level of upper bands of FZD9, which appear to be heterogenous, possibly due to heterogeneity of glycosylation. This is consistent with FZD9 maturation being inhibited by TMEM79. Other FZDs when overexpressed do not exhibit distinct bands of separable electrophoretic mobilities (data not shown) as do FZD5 most overtly and FZD9 to a lesser degree. (<bold>I</bold>) ZNRF3ΔRING, a mutant with the RING domain deletion, co-IPs mature FZD5 and immature FZD5 (possibly during ZNRF3ΔRING’s transit through the ER to PM). Because the full-length ZNRF3 reduces FZD levels, we employed ZNRF3ΔRING, which does not have the E3 ligase function, to avoid fluctuations of the FZD5 level in the co-IP assay. (<bold>J</bold>) Lysosome inhibitor bafilomycin A1 (BAF A1), but not proteasome inhibitor MG132, inhibits TMEM79-induced degradation of immature FZD5. BAF A1 increases both mature and immature forms of FZD5 (compare lanes 1 and 3). BAF A1 blocks TMEM79-induced degradation of immature FZD5, but does not increase mature FZD5 (compare lanes 3 and 4), consistent with the notion that TMEM79 prevents FZD maturation to the PM by shuttling FZD5 to the lysosome. MG132 does not affect levels of immature and mature FZD5 in the absence (compare lanes 1 and 5) or presence of TMEM79 (compare lanes 2 and 6). Thus it appears that ZNRF3 and RNF43 promote degradation of mature FZD5 through the lysosome (<xref ref-type="bibr" rid="bib25">Koo et al., 2012</xref>), whereas TMEM79 promotes degradation of immature FZD5 through the lysosome.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56793-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>TMEM79 binds to and promotes degradation of FZD as an ER-resident protein</title><p>TMEM79, upon overexpression, co-immunoprecipitated (IPed) endogenous FZD5 but not LRP6 in HEK293T cells (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Interestingly, TMEM79 was co-IPed with each of the 10 FZD proteins (FZD1-10) in humans, but not with Smoothened (SMO), which is a distant member of the FZD subfamily of serpentine receptors and required for Shh signaling (<xref ref-type="fig" rid="fig3">Figure 3G</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). This result demonstrates exquisite TMEM79-FZD binding specificity that mirrors TMEM79 functional specificity (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). FZD5 expression resulted in two discrete protein bands (<xref ref-type="bibr" rid="bib61">Yamamoto et al., 2005</xref>; <xref ref-type="bibr" rid="bib25">Koo et al., 2012</xref>): the upper/slow-migrating one reflected mature/fully glycosylated FZD5 at the PM and could be labeled using cell-surface protein biotinylation, while the lower/fast-migrating band represented immature/un-glycosylated FZD5 mostly at the ER during biogenesis and was not labeled by surface protein biotinylation (<xref ref-type="fig" rid="fig3">Figure 3H and I</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>). TMEM79 co-IPed the immature FZD5 only (<xref ref-type="fig" rid="fig3">Figure 3I</xref>), but caused reduction of mature FZD5 at the PM as ZNRF3 did (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Similarly, TMEM79 appeared to preferentially co-IP the lower/fast-migrating band of FZD9, presumably the immature FZD9 form, while reduced the level of FZD9 at upper/slow-migrating bands that likely reflect heterogeneity of FZD9 glycosylation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H</xref>). Note that ZNRF3 was but TMEM79 was not surface-biotinylated (<xref ref-type="fig" rid="fig3">Figure 3H</xref>), suggesting that TMEM79 may not be localized at the PM. FZD5-K0, a mutant FZD5 with cytoplasmic lysine (K) residues replaced by arginine (R) residues, was resistant to reduction of its cell surface level by ZNRF3 or by TMEM79 (<xref ref-type="fig" rid="fig3">Figure 3J</xref>), implying involvement of FZD5 ubiquitination in the action of TMEM79 as in that of ZNRF3 (<xref ref-type="bibr" rid="bib18">Hao et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Koo et al., 2012</xref>). Unlike TMEM79, however, ZNRF3 co-IPed mature FZD5 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1I</xref>), consistent with its action at the PM as an Rspo receptor (<xref ref-type="bibr" rid="bib18">Hao et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Koo et al., 2012</xref>). It seems likely that TMEM79 and ZNRF3 promote FZD degradation through ubiquitination at the ER and PM, respectively, reflecting their independent action that each leads to reduction of FZD at the PM.</p><p>Our results suggest that TMEM79 acts primarily at the ER. Immunostaining via confocal microscopy showed localization of endogenous TMEM79 at the ER predominantly and the lysosome to some extent, but not or little at the Golgi or PM (<xref ref-type="fig" rid="fig4">Figure 4</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), corroborating results from biochemical analyses. Lysosomal inhibitor Bafilomycin A1 (Baf A1), but not proteasomal inhibitor MG132, resulted in elevated levels of both immature and matured forms of FZD5, suggesting lysosomal degradation of both forms of FZDs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1J</xref>). Indeed degradation of matured FZD by ZNRF3/RNF43 is prevented by Baf A1 and is thus mediated by the lysosome as suggested (<xref ref-type="bibr" rid="bib25">Koo et al., 2012</xref>). Noticeably, Baf A1 blocked immature FZD5 degradation without increasing the level of matured FZD5 at the PM (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1J</xref>), consistent with the notion that TMEM79 directs FZD from the ER to the lysosome, from which undegraded FZD is not retrievable. Baf A1 apparently also prevented lysosomal degradation of TMEM79 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1J</xref>), which is found in the lysosome (<xref ref-type="fig" rid="fig4">Figure 4</xref>) and probably chaperones FZD to degradation there. Alternatively or additionally TMEM79 protein itself may be regulated through a lysosomal degradation pathway.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>TMEM79 is likely an ER-resident protein.</title><p>(<bold>A to D</bold>) Immunofluorescence microscopy of endogenous TMEM79 (red) with ER, PM, lysosome, and Golgi markers (green), respectively, with the nucleus labeled by DAPI (blue). The z-axis is shown on right and underneath. The white scale bar represents 10 µm. Fluorescence intensity of TMEM79 and the respective marker is measured between the two arrowheads in the lower left panel and plotted at lower right. (<bold>A</bold>) TMEM79 is localized at the ER. TMEM79 and calreticulin (an ER marker) overlap extensively in images and intensity traces. (<bold>B</bold>) TMEM79 is not present at the PM, which is visualized by β-catenin-EGFP (produced from the endogenous β-catenin gene with an in-frame knock-in of the EGFP gene, see Materials and methods). Note that β-catenin is predominantly localized at the PM in epithelial cells. (<bold>C</bold>) Some TMEM79 is observed at the lysosome. TMEM79 and LAMP1 (lysosomal-associated membrane protein 1) overlap occasionally. (<bold>D</bold>) TMEM79 is hardly observed at the Trans Golgi and exhibits little or minor overlap with TGN46 (trans-Golgi marker 46).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>TMEM79 is an ER-resident protein.</title><p>(<bold>A</bold>) TMEM79 is not detectable by the TMEM79 antibody without cell permeabilization. Note that the antibody (Key Resources Table) recognizes the TMEM79 C-terminus (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), which is either in the ER lumen, or extracellular if TMEM79 were to be on the PM. This result is consistent with TMEM79 being an ER- but not PM-resident protein. (<bold>B</bold>) T79KO cells lack TMEM79 staining completely, demonstrating specificity of the TMEM79 antibody for immunostaining. Scale bar = 10 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>TMEM79 is associated with USP8 and inhibits its deubiquitination of FZD</title><p>TMEM79 does not have any known functional motif. We performed tandem-affinity purification for TMEM79-interacting proteins (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Mass spectrometry revealed a dozen proteins (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), among which is USP8 (also called UBPy). Of Interest, USP8 has been implicated in deubiqutination of various transmembrane proteins including Fzd and Smo in <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bib39">Mukai et al., 2010</xref>; <xref ref-type="bibr" rid="bib60">Xia et al., 2012</xref>), and EGF receptor and other receptor tyrosine kinases (RTKs) in mammalian cells, thereby enhancing signaling by Wnt, Shh, and RTKs (<xref ref-type="bibr" rid="bib37">Mizuno et al., 2005</xref>; <xref ref-type="bibr" rid="bib50">Row et al., 2006</xref>; <xref ref-type="bibr" rid="bib1">Alwan and van Leeuwen, 2007</xref>; <xref ref-type="bibr" rid="bib41">Niendorf et al., 2007</xref>). Oncogenic activation of USP8 by mutations or chromosomal translocation underlie Cushing’s disease (caused by a pituitary adenoma <xref ref-type="bibr" rid="bib32">Ma et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Reincke et al., 2015</xref>) and leukemia (<xref ref-type="bibr" rid="bib22">Janssen et al., 1998</xref>), respectively, and USP8 overexpression is associated with poor prognosis of lung and cervical cancer cases (<xref ref-type="bibr" rid="bib24">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib62">Yan et al., 2018</xref>). But regulation of USP8 and its substrate specificity is not well understood (<xref ref-type="bibr" rid="bib28">Leznicki and Kulathu, 2017</xref>). Interestingly the endogenous USP8 protein exhibits predominant localization at intracellular membranes resembling the ER (<xref ref-type="bibr" rid="bib41">Niendorf et al., 2007</xref>), consistent with USP8 acting on transmembrane protein substrates during biogenesis and being a potential partner of TMEM79. We therefore investigated TMEM79-USP8 biochemical and functional relationships. USP8C, which represents the C-terminal half of the protein containing the deubiquitination enzyme (DUB) domain (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) and is probably a mutationally activated form generated in Cushing’s disease (<xref ref-type="bibr" rid="bib48">Reincke et al., 2015</xref>), induced the TOP-Flash reporter as reported (<xref ref-type="bibr" rid="bib39">Mukai et al., 2010</xref>), and this induction was inhibited by IWP-2 (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), consistent with USP8 acting through FZD stabilization (<xref ref-type="bibr" rid="bib39">Mukai et al., 2010</xref>). Importantly, TMEM79 inhibited USP8C-activation of TOP-Flash (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). USP8C, but not USP8N, the N-terminal half of USP8, co-IPed TMEM79 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), confirming our results by tandem affinity purification. We generated a series of TMEM79 truncation mutants (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Only the full length TMEM79 and TMEM79ΔC exhibited the ability to interact with USP8C and to down-regulate the FZD5 level at the PM (<xref ref-type="fig" rid="fig5">Figure 5E,F</xref>). Other truncation mutants were each inactive in both assays (<xref ref-type="fig" rid="fig1">Figures 1D</xref> and <xref ref-type="fig" rid="fig5">5D,F</xref>). Thus, the ability of TMEM79 or its mutants to down-regulate the FZD5 level at the PM was fully correlated with its capacity to associate with USP8. Note that TMEM79 (1-280) is inactive and is the underlying mutation in <italic>matted</italic> mice, which exhibited skin inflammation that models human AD (<xref ref-type="bibr" rid="bib53">Sasaki et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Saunders et al., 2013</xref>). Thus the <italic>Tmem79 matted</italic> allele represents a functional null. Our mutational analysis is consistent with sequence conservation pattern among Tmem79 proteins from different species (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) and genetic studies showing <italic>matted</italic> and Tmem79 KO mice sharing indistinguishable AD phenotypes (<xref ref-type="bibr" rid="bib12">Emrick et al., 2018</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>TMEM79 inhibits Frizzled (FZD) deubiquitination by USP8.</title><p>(<bold>A</bold>) Schematic diagram of USP8. USP8N, USP8 N terminal fragment; USP8C, USP8 C terminal fragment. Known domains including DUB and a 14-3-3-binding motif are depicted. (<bold>B</bold>) Activation of Top-Flash by USP8C is inhibited by IWP-2 or by TMEM79. (<bold>C</bold>) TMEM79 is co-IPed by USP8C or USP8CΔ (with the 14-3-3 binding motif deleted), but not by USP8N, suggesting that USP8C (but not its 14-3-3 binding motif) is involved in TMEM79 interaction. (<bold>D</bold>) Schematic diagram of TMEM79 and its deletion mutants. Five transmembrane (TM) regions are depicted. (<bold>E</bold>) TMEM79 (FL, full length) or TMEM79-ΔC, but none of the other TMEM79 mutants, co-IPs USP8C. (<bold>F</bold>) TMEM79 or TMEM79-ΔC, but none of the other TMEM79 mutants, down-regulates the level of mature FZD5. (<bold>G</bold>) The Wnt response in USP8-KO cells is reduced and is not inhibited by TMEM79. (<bold>H and I</bold>) TMEM79 inhibits USP8C deubiquitination of FZD5 (<bold>H</bold>), but not SMO (<bold>I</bold>). HEK293T cells were cotransfected with V5-FZD5 and His-ubiquitin, and in combination with USP8C, TMEM79 or ZNRF3 as indicated. Ubiquitinated proteins were precipitated by Ni-NTA (nickel-nitrilotriacetic acid–agarose beads for His tag pull-down), followed by wash in 7M urea to fully disassociate all protein complexes. Ubiquitinated V5-FZD5 was then precipitated by anti-V5 agarose beads. These multiple steps ensured detection of ubiquitinated V5-FZD5 only, but not V5-FZD5-associated proteins that are also ubiquitinated. Levels of ubiquitinated FZD5 were increased by TMEM79 or ZNRF3 co-expression whereas USP8C deubiquitinated FZD5. TMEM79 inhibited USP8C deubiquitination of FZD5 and restored FZD5 ubiquitination (<bold>H</bold>). USP8C also deubiquitinated SMO, but TMEM79 had no effect on USP8C deubiquitination of SMO (<bold>I</bold>). (<bold>J</bold>) USP8 or USP8C preferentially co-IPs the immature form of FZD5 (the lower band).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56793-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Tandem affinity purification-coupled mass spectrometry identifies USP8 as a TMEM79 binding partner.</title><p>(<bold>A</bold>) Tandem affinity purified proteins were resolved by SDS-PAGE and visualized by silver staining. The same tandem IP procedure of EGFP-expressing cell extracts serves as a negative control. The TMEM79 bait protein is marked, as is the gel fraction that corresponds to the molecular weight of USP8. (<bold>B</bold>) List of candidate proteins from tandem affinity purification-coupled mass spectrometry. Note that only a few visible fractions/bands in A were excised and pooled together for mass spectrometry analyses (see Materials and methods). The list is therefore not intended to be a comprehensive representation of all candidate TMEM79-associated proteins. (<bold>C</bold>) Genomic DNA sequencing showing indel (frame shift) mutations of <italic>USP8</italic> alleles in a USP8 KO clone picked/used. Two clones were picked and tested with indistinguishable results (data not shown). (<bold>D</bold>) ZNRF3 inhibits top-flash reporter activity effectively in <italic>USP8</italic> KO cells. (<bold>E</bold>) FZD5 co-IPs USP8 in the absence of TMEM79 in T79KO cells. (<bold>F</bold>) Overexpression of TMEM79 does not affect FZD5 co-IP of USP8. This experiment largely rules out a scenario that TMEM79 inhibits USP8 deubiquitination of FZD5 by competing with FZD5 for USP8. TMEM79 is also co-IPed by FZD5. (<bold>G</bold>) USP8 co-IPs TMEM79 in in FZD null cells.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-56793-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig5-figsupp1-v2.tif"/></fig></fig-group><p>USP8 KO HEK293T cells exhibited Wnt responsiveness but at a significantly reduced level (<xref ref-type="fig" rid="fig5">Figure 5G</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>), reflecting USP8 promoting FZD deubiquitination and stabilization. Importantly, inhibition of the Wnt response by TMEM79, but not by ZNRF3, was abolished in USP8 KO cells (<xref ref-type="fig" rid="fig5">Figure 5G</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>), demonstrating that TMEM79 acts strictly through USP8. USP8C promoted deubiquitination of both FZD5 and SMO as reported (<xref ref-type="bibr" rid="bib39">Mukai et al., 2010</xref>; <xref ref-type="bibr" rid="bib60">Xia et al., 2012</xref>), but TMEM79 inhibited USP8C deubiquitination of FZD5, but not SMO (<xref ref-type="fig" rid="fig5">Figure 5H,I</xref>), demonstrating a stringent control by TMEM79 on USP8 specificity towards FZD. This deubiquitination result corroborates both TMEM79 inhibition of Wnt but not Shh signaling (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) and TMEM79 binding to FZD but not SMO (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). Interestingly USP8 or USP8C associated preferentially with immature FZD5 (<xref ref-type="fig" rid="fig5">Figure 5J</xref>) as does TMEM79, consistent with predominant localizations of USP8 at intracellular membranes that resemble the ER (<xref ref-type="bibr" rid="bib41">Niendorf et al., 2007</xref>). It therefore appears that immature FZD is a primary substrate of USP8.</p><p>Given the binary protein interactions we observed among FZD, TMEM79, and USP8, we further examined how their complex assembly might occur and lead to inhibition of USP8 by TMEM79. We found that FZD-USP8 interaction was observed in TMEM79 KO cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>) and thus is not mediated by TMEM79. FZD-USP8 interaction was unaffected by TMEM79 overexpression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>), ruling out a scenario that TMEM79 competes with FZD for USP8-binding to achieve inhibition of FZD deubiquitination by USP8. Conversely TMEM79-USP8 interaction was unaffected in FZD null cells in which all 10 FZD genes have been deleted (<xref ref-type="bibr" rid="bib13">Eubelen et al., 2018</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1G</xref>), and is thus not mediated by FZDs. These data together suggest that the assembly of the FZD-USP8-TMEM79 complex, in which USP8 action on FZD is inhibited specifically, probably is multivalent in nature and involves additional proteins yet to be identified.</p></sec><sec id="s2-5"><title>Tmem79 inhibition of Wnt/β-catenin signaling in naive ectoderm is required for anterior and neural development in <italic>Xenopus</italic> embryos</title><p>The Tmem79 gene is antient and found throughout the animal kingdom, from cnidarians, protostomes, to deuterostomes including all vertebrates examined, but appears to be absent in <italic>Drosophila</italic> and nematodes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; See Discussion). We examined Tmem79 functions in <italic>Xenopus</italic>, which like other vertebrates employs Wnt signaling for anterioposterior (AP) patterning during early embryogenesis (<xref ref-type="bibr" rid="bib11">De Robertis and Kuroda, 2004</xref>; <xref ref-type="bibr" rid="bib40">Niehrs, 2004</xref>). Tmem79 is expressed maternally and broadly throughout embryogenesis (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), including in the animal, vegetal, dorsal, and ventral regions in early gastrula (stage 10.5) embryos (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Whole mount in situ hybridization showed Tmem79 expression in animal blastomeres at the four-cell stage and stage 6.5, and broadly in the animal region in blastula (stages 8.5 and 9.5) and early gastrula embryos (stages 10 and 10.5) with strong expression in naive ectoderm (<xref ref-type="fig" rid="fig6">Figure 6C</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). During neurula stages Tmem79 is detected initially in the anterior neural plate but is subsequently excluded from CNS primordia (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Thus, Tmem79 exhibits broad and dynamic expression during <italic>Xenopus</italic> early embryogenesis, including during neural induction and AP patterning.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>Xenopus</italic> Tmem79 is required in naive ectoderm for anterior and neural development.</title><p>(<bold>A</bold>) Tmem79 is expressed throughout <italic>Xenopus embryogenesis</italic> from 1 cell (fertilized egg) to stage (st) 30, spanning blastula, gastrula, neurula and tailbud/organogenesis stages, as assayed by RT-PCR. (<bold>B</bold>) Tmem79 is expressed in dissected animal, vegetal, dorsal, and ventral regions (as schemed in drawing) of early gastrula embryos (stage 10.5). xnr3 is a control for dorsal. (<bold>C</bold>) Tmem79 expression during <italic>Xenopus</italic> embryogenesis by whole-mount in situ hybridization. An apparent lack of hybridization signals in vegetal pole and derived tissues is likely technical due to yolk. Top row (c1 to c6) Tmem79 is expressed in the animal pole at the four-cell stage and in naive ectoderm at blastula stages: (c1) Dorsal-animal view; (c2 to c4) Lateral-animal views; (c5 and c6) Lateral and bisected views. Second row (c7 to c12) Tmem79 is expressed broadly in naive ectoderm at early gastrula stages: (c7 and c8) dorsal-vegetal and lateral views with the arrow pointing to the dorsal; (c9) bisected view with an enlarged view (c10) showing expression in naive ectoderm; (c11 and c12) lateral and bisected views. Anterior to top in c11. Third row (c13 to c18) Tmem79 shows dynamic expression from late gastrula to neurula stages: (c13 and c14) lateral and bisected views showing broad expression including in neural plate. Anterior to top in c13 and left in c14. (c15 to c17) Dorsal views. Anterior to top. Tmem79 expression is downregulated in neural plate while remains strong in epidermis, as seen also in a cross-section (c18) along the dashed line in c17. (c18) an enlarged cross-section view with dorsal on top. Bottom row (c19 to c23) Tmem79 is expressed during organogenesis: (c19 and c20) Lateral and anterior views showing expression in the cement gland. (c21 and c22) A lateral view with an enlarged view (anterior to right) and (c23) a ventral view (anterior to top) showing expression in primitive kidney (black arrows) and otic vesicle (white arrows). (<bold>D and E</bold>) Dorsal-animal (naive ectoderm) injection of Tmem79MO causes anterior deficiency, which is rescued/over-rescued by co-injection of mouse Tmem79 mRNA or Usp8MO or β-cateninMO. CoMO, Control Morpholino. Anterior to right (<bold>E</bold>). Also see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A</xref>. (<bold>F</bold>) Tmem79MO reduces neural plate formation and reciprocally expands epidermal differentiation, reflected by Sox2 and cytokeratin expression domains at Stage 16, respectively. These changes are rescued by Tmem79 mRNA or Usp8MO. Anterior to right. Also see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1C</xref>. (<bold>G</bold>) Neural induction by Noggin in animal pole explants is prevented by Tmem79MO, whose effect is rescued by Tmem79 mRNA or Usp8MO or β-cateninMO. Pan-neural (n-cam), anterior (bf1, otx2, and six3) and mid/hind (en2 and krox20) brain markers and a neuronal differentiation marker (n-tub) are assayed, as is an epidermal marker (keratin).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title><italic>Xenopus</italic> tmem79 is required for anterior neural patterning and neural crest formation without affecting the head organizer.</title><p>(<bold>A</bold>) A Tmem79 sense probe as a negative control does not show any hybridization signal in embryos at different stages. (<bold>B</bold>) Dorsal injection of Tmem79 mRNA induces an enlarged head in &gt;50% embryos and spina bifida in another about 30% embryos. Anterior to right. Also see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1G</xref>. (<bold>C</bold>) Tmem79MO inhibits protein synthesis from the <italic>Xenopus</italic> Tmem79 (xTmem79) mRNA, but not of the mouse Tmem79 (mT79) mRNA, which is used in rescue experiments. GAPDH is a protein loading control. (<bold>D</bold>) Usp8MO inhibits protein synthesis from the <italic>Xenopus</italic> Usp8 (xUsp8) mRNA, but not from a mutant Usp8 (x-mutUsp8) mRNA, in which several nucleotides in xUsp8 5’-UTR targeted by the MO have been altered. (<bold>E</bold>) Dorsal-animal injection of Tmem79 MO reduces expression of anterior and mid/hind brain markers Bf1, Krox20, and En2, an anterior (cement gland) marker Xag (each seen in the anterior view), and a neuronal marker n-tubulin (see in the dorsal view), examined at stage 16. Co-injection of mTmem79 with Tmem79MO rescues expression of these markers. Also see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1H</xref>. (<bold>F</bold>) Dorsal-animal injection of β-cateninMO or Usp8MO leads to enlarged head formation at the tailbud stage (anterior to right), supporting Usp8 acting positively in Wnt/β-catenin signaling in vivo. Also see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1I</xref>. (<bold>G</bold>) Dorsal-animal injection of Tmem79MO affects neither expression of head organizer genes (Goosecoid, Chordin, Dkk1, and Lim1) nor that of dorsal genes (xnr3 and xnot) at stages 10.5–11. Vegetal views with dorsal to top. Also see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1J</xref>. (<bold>H</bold>) Dorsal-animal injection of Tmem79MO reduces expression of neural crest markers FoxD3 and snail1 examined at stage 16. Also see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1K</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Injection of Tmem79 mRNA dorsally caused, in over 50% of embryos, an enlarged head indistinguishable from that caused by overexpression of other Wnt antagonists (<xref ref-type="bibr" rid="bib17">Glinka et al., 1998</xref>; <xref ref-type="bibr" rid="bib64">Zhang et al., 2012</xref>); Additionally, spina bifida was observed in another 30% embryos subjected with Tmem79 mRNA dorsal injection (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), hinting at possible roles of Tmem79 in both AP patterning and morphogenesis. We generated an antisense morpholino oligonucleotide (MO) against Tmem79, Tmem79MO, which blocked synthesis of <italic>Xenopus</italic> Tmem79 protein specifically (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Depletion of Tmem79 from the animal region/naive ectoderm by Tmem79MO resulted in deficiency in anterior development and anterior gene expression, both of which were rescued by mouse Tmem79 mRNA (<xref ref-type="fig" rid="fig6">Figure 6D,E</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>), demonstrating the MO specificity. Importantly, the anterior deficiency by Tmem79 depletion was rescued/over-rescued by co-depletion of either β-catenin or Usp8 through respective MOs (<xref ref-type="bibr" rid="bib20">Heasman et al., 2000</xref>; <xref ref-type="fig" rid="fig6">Figure 6D,E</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>). Thus, Tmem79 has an obligatory function in naive ectoderm as a Wnt antagonist for anterior patterning through inhibition of Usp8 and β-catenin signaling, corroborating biochemical data in human cells. We note that depletion of Usp8 alone in naive ectoderm resulted in enlarged head formation, as did depletion of β-catenin alone as reported (<xref ref-type="bibr" rid="bib20">Heasman et al., 2000</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>), accounting for the over-rescuing effect observed in some embryos (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) and reinforcing the notion that Usp8 acts positively in Wnt/β-catenin signaling in vivo. Tmem79 depletion in naive ectoderm did not affect gene expression in dorsal Spemann-Mangold Organizer (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>), and thus Tmem79 is required in naive ectoderm for anterior development without perturbing organizer function.</p><p>Depletion of Tmem79 in naive ectoderm also led to a reduction of neural plate formation in the embryo (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). In a classical neural induction assay, animal pole explants from control embryos (or embryos injected with a control MO) were neuralized by BMP antagonist Noggin ex vivo, but those from Tmem79MO injected embryos failed to do so and instead adopted an epidermal fate in the presence of Noggin (<xref ref-type="fig" rid="fig6">Figure 6G</xref>), indicating a requirement of Tmem79 in naive ectoderm for neural fate determination. The neural plate deficiency in vivo and incapability of neuralization in explants caused by Tmem79 depletion were rescued by mouse Tmem79 mRNA, and by co-depletion of β-catenin or Usp8 (<xref ref-type="fig" rid="fig6">Figure 6F,G</xref>). Thus, Tmem79 is required in naive ectoderm for early CNS formation through inhibition of Usp8 and β-catenin signaling.</p><p>We noted that depletion of Tmem79 drastically reduced pigmentation in embryos (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), implying a defect in melanocytes, which are derived from neural crest precursors formed at the border of neural plate. Indeed Tmem79 depletion diminished expression of neural crest markers Foxd3 and Snail1 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1H</xref>). Furthermore, pigmentation deficiency by Tmem79 depletion was rescued by co-depletion of Usp8 or β-catenin (<xref ref-type="fig" rid="fig6">Figure 6E</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1B</xref>). Therefore, inhibition of Wnt/β-catenin signaling by Tmem79 is also required for neural crest formation and thus subsequent melanocyte production.</p></sec><sec id="s2-6"><title>Tmem79 is required for FZD/PCP signaling in axial mesoderm and regulates gastrulation in <italic>Xenopus</italic> embryos</title><p>FZD is a core component of FZD/PCP signaling, which regulates convergent-extension (CE) cell movements in dorsal axial mesoderm and plays a central role in vertebrate gastrulation (<xref ref-type="bibr" rid="bib63">Yang and Mlodzik, 2015</xref>; <xref ref-type="bibr" rid="bib3">Butler and Wallingford, 2017</xref>). A cardinal feature of FZD/PCP signaling is that either up- or down-regulation results in PCP defects and perturbation of CE movements, underscoring the importance of fine-tuning the pathway. Injection of Tmem79MO or Tmem79 mRNA dorsally (in future axial mesoderm) caused spina bifida (<xref ref-type="fig" rid="fig7">Figure 7A,B</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), which is commonly associated with gastrulation anomalies. Upon Tmem79 depletion, the axial mesodermal marker xNot was expressed apparently normally, but axial mesoderm failed to converge toward the midline and to elongate along the AP axis, causing the axial tissue to spread laterally and the embryo to exhibit failure in closure of the blastopore (<xref ref-type="fig" rid="fig7">Figure 7C,D</xref>). These gastrulation defects by Tmem79MO were significantly rescued by mouse Tmem79 mRNA (<xref ref-type="fig" rid="fig7">Figure 7A–D</xref>). Note that Tmem79 depletion in the animal pole (in future naive ectoderm) did not affect gastrulation but caused anterior deficiency (<xref ref-type="fig" rid="fig6">Figure 6D,E</xref>), consistent with the view that FZD/PCP signaling in dorsal axial tissue is the main driving force of CE movements during gastrulation (<xref ref-type="bibr" rid="bib3">Butler and Wallingford, 2017</xref>). Finally, animal pole explants can be induced by Nodal/Activin signaling to form axial mesoderm, which exhibits CE movements and elongation ex vivo reminiscent of gastrulation in vivo. Tmem79-depleted animal pole explants formed activin-induced axial mesodermal tissue, consistent with the observation that Tmem79 had no effect on nodal/activin signaling (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), but these explants failed to exhibit CE movements and axial elongation, (<xref ref-type="fig" rid="fig7">Figure 7E–G</xref>). Mouse Tmem79 mRNA or Usp8MO rescued the CE movement anomaly caused by Tmem79MO (<xref ref-type="fig" rid="fig7">Figure 7E–G</xref>). These data suggest a critical role of Tmem79 in FZD/PCP signaling and vertebrate gastrulation.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title><italic>Xenopus</italic> Tmem79 regulates Frizzled (FZD)/PCP signaling and convergent-extension (CE) cell movements in axial mesoderm.</title><p>(<bold>A to D</bold>) Dorsal (axial mesoderm) injection of Tmem79MO causes spina bifida scored at stage 26 (<bold>A and B</bold>), and a lack of CE movements of axial mesoderm, visualized by a widened (not elongated) xNot-expressing axial tissue and an open blastopore at stage 12 (<bold>C and D</bold>). Axial mesoderm elongation is rescued by Tmem79 mRNA (<bold>C and D</bold>). Anterior to right. Also see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1D and E</xref>. (<bold>E</bold> to <bold>G</bold>) Axial mesoderm induced by activin in animal pole explants exhibits CE movements, visualized by explant elongation and quantified by a length/width (L/W) ratio (<bold>E and F</bold>). Control explants are round with a L/W ratio of 1 while explants (axial mesoderm induced by activin) elongate with a L/W ratio of 3 (<bold>E and F</bold>). Explants with Tmem79MO poorly elongate but elongation is rescued by Tmem79 mRNA or Usp8MO (<bold>E and F</bold>). Also see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1F</xref>. Note that Tmem79MO alone or together with Usp8MO does not affect activin-induced axial mesoderm gene expression (<bold>G</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig7-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>TMEM79 defines a FZD degradation pathway</title><p>We have provided compelling evidence for a previously unrecognized FZD degradation pathway that involves ER-resident protein TMEM79. TMEM79 acts as a specific antagonist of Wnt/FZD signaling by complexing with FZD during biogenesis, apparently targeting FZD in the ER for lysosomal destruction (<xref ref-type="fig" rid="fig8">Figure 8</xref>). FZD degradation mediated by TMEM79 is independent of and complementary to that by the ZNRF3/RNF43-mediated endocytic-lysosomal pathway, which acts on FZD at the PM. These two FZD degradation pathways may act in parallel or in concert in different developmental/homeostatic contexts to ensure a low and rate-limiting FZD protein level at the PM and thus cellular responsiveness to the action of Rspo proteins, which stabilize/increase the FZD protein level through inhibition of ZNRF3/RNF43 (Rspo receptors) (<xref ref-type="bibr" rid="bib10">de Lau et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Hao et al., 2016</xref>). Mechanistically, TMEM79 forms a complex with FZD and USP8 and inhibits USP8 deubiquitination of FZD during biogenesis, thereby promoting trafficking of ubiquitinated FZD from ER to the lysosome for destruction (<xref ref-type="fig" rid="fig8">Figure 8</xref>). The capacity of TMEM79 to function as a Wnt/FZD signaling antagonist relies fully on its inhibition of USP8 and is abolished in USP8 KO cells. Our results highlight a synthesis-ubiquitination-destruction cycle for FZD from the ER to the lysosome, with USP8 acting to prevent FZD destruction and to allow FZD to mature to the PM (<xref ref-type="fig" rid="fig8">Figure 8</xref>). USP19, another member of the USP superfamily, has been shown to act in an analogous fashion during LRP6 biogenesis by preventing immature LRP6 in the ER from lysosomal destruction and enabling LRP6 to mature to the PM (<xref ref-type="bibr" rid="bib45">Perrody et al., 2016</xref>), suggesting independent and parallel governance for these Wnt receptors during their biogenesis. Ubiquitin ligases that ubiquitinate immature FZD and LRP6 remain to be identified.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>A working model of Frizzled (FZD) regulation by USP8 and TMEM79.</title><p>FZD is synthesized in the ER and is ubiquininated (by an unknown E3 ligase, not depicted). FZD deubiquitination by USP8 permits FZD to traffic to Golgi and PM ultimately. ER-resident TMEM79 acts by complexing with FZD and USP8 and inhibiting USP8 deubiquitination of FZD, thereby ensuring ubiquitinated FZD in the ER to traffic to the lysosome for degradation. For FZD that escapes TMEM79-mediated degradation and matures to the PM, ZNRF3 promotes FZD ubiquitination at the PM, leading to endosomal-lysosomal degradation of FZD. These two complementary mechanisms ensure a rate-limiting amount of FZD at the PM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig8-v2.tif"/></fig></sec><sec id="s3-2"><title>TMEM79 inhibition of FZD deubiquitination by USP8: control of USP8 substrate specificity</title><p>USP8 deubiquitinates and stabilizes various families of transmembrane receptors, including FZD, SMO, which is a distantly-related FZD family member, and EGFR and other RTKs, thereby promoting signaling by Wnt, Hedgehog, EGF, and other growth factors (<xref ref-type="bibr" rid="bib37">Mizuno et al., 2005</xref>; <xref ref-type="bibr" rid="bib1">Alwan and van Leeuwen, 2007</xref>; <xref ref-type="bibr" rid="bib41">Niendorf et al., 2007</xref>; <xref ref-type="bibr" rid="bib39">Mukai et al., 2010</xref>; <xref ref-type="bibr" rid="bib60">Xia et al., 2012</xref>). Mutational activation of USP8 underlies pathogenesis of pituitary adenoma/Cushing’s Disease and leukemia (<xref ref-type="bibr" rid="bib22">Janssen et al., 1998</xref>; <xref ref-type="bibr" rid="bib32">Ma et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Reincke et al., 2015</xref>), and USP8 expression correlates with poorer prognosis of lung and other cancers (<xref ref-type="bibr" rid="bib24">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib62">Yan et al., 2018</xref>). It has been unclear if and how the broad substrate selectivity of USP8 is governed. TMEM79 binds to FZD but not SMO and inhibits USP8 deubiquitination of FZD but not SMO, highlighting a mechanism by which the broad specificity of USP8, and by extension of other USPs, can be precisely controlled. The action and specificity of TMEM79 towards FZD contrasts with the action of Shisa, which promotes trapping of multiple families of receptors including FZD, SMO, and FGFR (FGF receptor) in the ER via an unknown mechanism (<xref ref-type="bibr" rid="bib61">Yamamoto et al., 2005</xref>). It remains to be understood mechanically how the FZD-TMEM79-USP8 complex incapacitates USP8 action on FZD.</p></sec><sec id="s3-3"><title>An ancient pre-bilaterian origin of <italic>Tmem79</italic> and <italic>Usp8</italic> genes during metazoan evolution</title><p>The Tmem79 gene is found in all vertebrates examined (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), but a homologous gene is found in neither <italic>Drosophila</italic> nor nematodes, two prominent invertebrate models. Interestingly however, a Tmem79 homologue is identifiable in cnidarians and protostomes such as annelids and molluscs and certain arthropods including the acari and crabs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="fig" rid="fig9">Figure 9A</xref>), suggesting that the Tmem79 gene is ancient and was present in the common cnidarian-bilaterian ancestor over 600 million years ago. Genome sequencing suggests that this eumetazoan ancestor harbored the complete repertoire of Wnt genes, and most or all Wnt antagonist genes, but subfamilies of Wnt genes and many of Wnt antagonist genes were lost during protostome evolution (<xref ref-type="bibr" rid="bib27">Kusserow et al., 2005</xref>; <xref ref-type="bibr" rid="bib21">Holstein, 2012</xref>). It therefore appears that the Tmem79 gene has experienced a similar/related loss in protostomes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="fig" rid="fig9">Figure 9A</xref>) as a result of its specific role in Wnt signaling.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>The phylogenetic preservation or loss in bilateria of <italic>Tmem79</italic> (<bold>A</bold>) and <italic>Usp8</italic> (<bold>B</bold>).</title><p><italic>Tmem79</italic> and <italic>Usp8</italic> are present throughout deuterostomes while exhibit frequent and similar losses in protostomes. Note that both genes are found in cnidaria and thus was likely present in the common cnidarian and bilaterian ancestor (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Preservation of <italic>Tmem79</italic> in protostomes is always accompanied by preservation of <italic>Usp8</italic>, but not vice versa. One such example is in arthropods: <italic>Tmem79</italic> is absent but <italic>Usp8</italic> is present in <italic>Drosophila</italic> while the Acari has <italic>Tmem79</italic> and <italic>Usp8</italic>. Neither gene is found and was probably lost in Xenacoelomorpha.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-56793-fig9-v2.tif"/></fig><p>As TMEM79 acts strictly through inhibition of USP8 in human cells, we reason that the usp8 gene must be present in cnidarians and protostome lineages that have preserved the Tmem79 gene if the same molecular mechanism is conserved throughout evolution. This appears to be the case: the Usp8 gene is also antient and found in cnidarians, protostomes, and deuterostomes including all vertebrates examined; but Usp8 also exhibits frequent loss during protostome evolution in a manner that overtly mirrors the loss of the Tmem79 gene (<xref ref-type="fig" rid="fig9">Figure 9</xref>). Importantly, the protostome lineages that preserve the Tmem79 gene invariably harbor the Usp8 gene, but not vice versa. For example, some arthropods (the acari and crabs) have both Tmem79 and Usp8 while fruit flies have Usp8 but not Tmem79, whereas nematodes have neither. This glimpse of evolutionary history of Tmem79 and usp8 is consistent with our biochemical and genetic analyses that TMEM79 acts strictly by inhibition of USP8 action on FZD. It seems conceivable that the Tmem79-Usp8 pair may have a primordial function in Wnt/FZD signaling in pre-bilaterians (<xref ref-type="bibr" rid="bib21">Holstein, 2012</xref>; <xref ref-type="bibr" rid="bib46">Petersen and Reddien, 2009</xref>), and that the pair have experienced losses in protostomes related to the loss of Wnt and Wnt antagonist genes. In addition to Wnt/FZD signaling, Cnidarians have Smo and RTK receptors (<xref ref-type="bibr" rid="bib35">Matus et al., 2008</xref>; <xref ref-type="bibr" rid="bib4">Chapman et al., 2010</xref>).It seems plausible that in pre-bilaterians Usp8 regulates these multiple signaling pathways while its action on FZD is specifically controlled by Tmem79 as we have observed in human cells and <italic>Xenopus embryos</italic>. Alternatively, FZD may be the primordial substrate of Usp8, which during evolution may have gained new functions on non-FZD substrates that are not subjected to control by Tmem79. Investigations in cnidarians and basal protostomes will help to address the origin of Tmem79-Usp8 specificity in Wnt/FZD signaling.</p></sec><sec id="s3-4"><title>Tmem79 regulates Wnt/β-catenin signaling for patterning and FZD/PCP signaling for gastrulation in <italic>Xenopus</italic> embryos</title><p>We examined potential roles of Tmem79 in vertebrate embryonic development using the <italic>Xenopus</italic> model. Tmem79 is expressed broadly during <italic>Xenopus</italic> early embryogenesis. Depletion of Tmem79 by targeting a specific antisense MO to naïve ectoderm results in deficiency in anterior development and neural plate formation, and a failure of neuralization of naïve ectoderm by neural inducer/BMP antagonist Noggin ex vivo. In addition, Tmem79 depletion also leads to a defect in neural crest formation. Thus Tmem79 is required for head development, neural fate determination, and neural plate border/neural crest formation. Importantly, these developmental defects of anterior, neural, and neural crest tissues are each rescued by co-depletion of Usp8 or β-catenin in naive ectoderm, substantiating the notion that Tmem79 is required for <italic>Xenopus</italic> early embryogenesis by inhibition of Usp8 and Wnt/β-catenin signaling. Our results support the model that Wnt inhibition in naïve ectoderm has an obligatory role, together with BMP inhibition, for neural fate determination in <italic>Xenopus</italic> as in chick embryos (<xref ref-type="bibr" rid="bib56">Stern, 2005</xref>; <xref ref-type="bibr" rid="bib65">Zhang et al., 2015</xref>). It is of interest to note that Wnt antagonists expressed in naive ectoderm, Tmem79 and Notum (<xref ref-type="bibr" rid="bib65">Zhang et al., 2015</xref>) are each required for anterior patterning and neuralization with apparently little or no functional redundancy, given that depletion of either leads to indistinguishable anterior neural deficiency. This strict requirement of Wnt antagonists in naïve ectoderm is more striking considering the fact that naive ectoderm is exposed to and regulated by a plethora of Wnt antagonists secreted by the Spemann-Mangold Organizer (<xref ref-type="bibr" rid="bib11">De Robertis and Kuroda, 2004</xref>; <xref ref-type="bibr" rid="bib40">Niehrs, 2004</xref>). It appears that naive ectoderm must minimize Wnt signaling autonomously in order for anterior brain development to proceed in response to organizer-derived Wnt antagonists and BMP antagonists. The embryonic basis for this stringent requirement of Wnt signaling supression during early CNS formation remains to be understood.</p><p>Dorsal axial mesoderm drives gasrulation via CE cell movements, which are governed by FZD/PCP siganling that is distinct from the Wnt/β-catenin pathway (<xref ref-type="bibr" rid="bib63">Yang and Mlodzik, 2015</xref>; <xref ref-type="bibr" rid="bib3">Butler and Wallingford, 2017</xref>). Targeted depletion of Tmem79 in axial mesoderm, but not in naive ectoderm, resulted in purturbation of CE movements and gastrulation, reflecting a critical role Tmem79 in FZD/PCP signaling in the axial tissue. Co-depletion of Usp8 rescued CE movements, underscoring the antagonostic relationship between Usp8 and Tmem79 in regulating the FZD level and thus FZD/PCP signaling. Our data highlight multiple key functions of Tmem79 in <italic>Xenopus embryogenesis</italic> through governing different Wnt/FZD pathways, such as Wnt/β-catenin signaling in naive ectoderm for cell fate determination/patterning and FZD/PCP signaling in axial mesoderm for CE cell movements.</p><p>Mice null for Tmem79, that is, <italic>matted</italic> and <italic>Tmem79</italic> KO mice, exhibit overtly normal embryogenesis and are viable (<xref ref-type="bibr" rid="bib53">Sasaki et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Saunders et al., 2013</xref>; <xref ref-type="bibr" rid="bib12">Emrick et al., 2018</xref>). As Tmem79 exhibits dynamic expression during early mouse development based on a spatiotemporal transcriptome analysis (<xref ref-type="bibr" rid="bib44">Peng et al., 2019</xref>). It seems that Tmem79 may have a non-essential role, or more likely, may have a redundant role with Znrf3/Rnf43 or other Wnt antagonists during mouse embryogenesis. Functional redundancies among Wnt antagonists have been frequently observed in mice with genetic KO of individual Wnt antagonist genes in many cases, likely reflecting a fail-safe system built for Wnt signaling circuits (<xref ref-type="bibr" rid="bib8">Cruciat and Niehrs, 2013</xref>). Why does deficiency of Tmem79 (or of other Wnt antagonists) leads to strong developmental phenotypes in <italic>Xenopus</italic> but not in mouse embryos? One possibility is that there appears to be significant maternal Wnt expression in the egg (data not shown), which may persist in early <italic>Xenopus</italic> embryos, and the action of multiple Wnt antagonists together is required to counter this influence for embryogenesis to proceed; on the other hand, the maternal Wnt influence may be minimal or limited in the mouse, and the requirement of individual Wnt antagonist may be less stringent. Another possibility is that genetic deletion is often accompanied by genetic compensation that may not occur during acute knockdowns via the MO antisense technique (<xref ref-type="bibr" rid="bib49">Rossi et al., 2015</xref>). Despite of the apparent difference between <italic>Xenopus</italic> and mice in the requirement of individual Wnt antagonists, the underlying mechanism of Wnt regulation of the developmental processes is likely conserved. </p></sec><sec id="s3-5"><title>Implications to understanding TMEM79 in AD pathogeneisis</title><p>Interestingly, <italic>matted</italic>/<italic>Tmem79</italic> KO mice exhibit skin barrier anomaly and inflammation reminiscent of AD in humans, and <italic>TMEM79</italic> is an AD predisposition gene (<xref ref-type="bibr" rid="bib53">Sasaki et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Saunders et al., 2013</xref>; <xref ref-type="bibr" rid="bib12">Emrick et al., 2018</xref>). Skin barrier malformation/malfunction is believed to be a major initiator for AD pathogenesis, which involves both the skin and the immune system (<xref ref-type="bibr" rid="bib38">Mu et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">McLean, 2016</xref>; <xref ref-type="bibr" rid="bib58">Weidinger and Novak, 2016</xref>). Tmem79/TMEM79 is expressed in keratinocytes and the skin barrier in mice and humans (<xref ref-type="bibr" rid="bib53">Sasaki et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Saunders et al., 2013</xref>), and keratinocyte-specific deletion of Tmem79 in mice results in skin barrier defects and much of the AD phenotypes (<xref ref-type="bibr" rid="bib12">Emrick et al., 2018</xref>). The barrier is formed by differentiated keratinocytes derived from interfollicular epidermal stem cells (<xref ref-type="bibr" rid="bib31">Lim and Nusse, 2013</xref>; <xref ref-type="bibr" rid="bib57">Watt, 2014</xref>; <xref ref-type="bibr" rid="bib15">Fuchs, 2016</xref>), which self-renew through autocrine Wnt/β-catenin signaling and differentiate into keratinocytes when Wnt signaling is dampened (<xref ref-type="bibr" rid="bib7">Choi et al., 2013</xref>; <xref ref-type="bibr" rid="bib30">Lim et al., 2013</xref>). In light of these and other observations (<xref ref-type="bibr" rid="bib2">Augustin et al., 2013</xref>), we speculate that TMEM79 deficiency may result in elevated Wnt signaling that perturbs keratinocyte differentiation and skin barrier integrity, leading to AD pathogenesis. Further experiments will be required to examine this hypothesis.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Plasmids</title><p>Mouse Tmem79 was tagged with Myc or Flag or both at the C-terminus. FZD1-10 were tagged with 2xHA or V5 epitope right after the signal peptide. HA-USP8 was generated by PCR-subcloning using Flag-HA-USP8 (Addgene, #22608) as template. V5-FZD5-K0 was generated by site-directed mutagenesis (cytoplasmic lysines 347, 434, 439, 442, 445, 525, 546 and 578 were substituted with arginines). ZNRF3-HA was a gift from Dr. Feng Cong. HA tag in pcDNA3-HA-Ubiquitin (Addgene, #18712) was replaced with 6xHis by PCR cloning to make His-Ubiquitin. <italic>Xenopus laevis tmem79</italic> and <italic>usp8</italic> cDNAs were PCR amplified from <italic>Xenopus</italic> stage 10 cDNA library and cloned into pCS2+ vector. SuperTopflash vector 7TFP was obtained from Addgene (#24308). <italic>Renilla</italic> was PCR amplified from pRL-TK (Promega) and subcloned into lentiviral vector pHage-EF1α. To make lentiviral Top-EGFP reporter plasmid, 7xTCF promoter and EGFP were amplified from 7TFP and pEGFP-N1 (Clontech) vectors, respectively, and subcloned into lentiviral vector pHage.</p></sec><sec id="s4-2"><title>Generating top-EGFP stable line and genome wide CRISPR/Cas9 screening and data analysis</title><p>HEK293T cells were transduced with Top-EGFP lentivirus. Monoclonal cell populations that were GFP positive after Wnt3a treatment were manually selected in 96-well plates and expanded for screening. We performed positive selection screen for negative Wnt/β-catenin regulators following published protocols using human GeCKO v.2 sgRNA library (Addgene #1000000049) (<xref ref-type="bibr" rid="bib52">Sanjana et al., 2014</xref>). Briefly, we transduced Top-EGFP cells with GeCKO library at MOI (multiplicity of infection) of ~0.3. After selection by puromycin for 2 weeks, GFP positive cells were sorted by BD FACSAriaII cell sorter and cultured for additional 4 days. Genomic DNA of the sorted cells was extracted using the Blood and Cell Culture DNA mini kit (Qiagen). The genomic region containing gRNAs was PCR-amplified. PCR products from 10 independent reactions were purified using QIAquick Gel Extraction Kit (Qiagen) and pooled for deep sequencing. We used Mageck to analyze the sequencing data (<xref ref-type="bibr" rid="bib29">Li et al., 2014</xref>). All reads in fastq files were mapped to the sgRNA library and a list of genes based on raw read counts was generated. Top-ranked genes with high numbers (3 to 6) of unique sgRNAs and high read counts were validated using two or more shRNAs.</p></sec><sec id="s4-3"><title>Cell culture, immunofluorescence, RNA interference and dual luciferase assay</title><p>HEK293T cells were obtained from ATCC (ATCC# CRL-11268) with a certificate of authentication with STR profiling. Cell lines were confirmed to be mycoplasma-negative when cultures were started in the lab. HEK293T cell line and its derivatives were maintained in DMEM supplemented with 10% FBS, penicillin, and streptomycin. ZRKO (ZNRF3 and RNF43 double knockout) cell line was a gift from F. Cong. The FZD null cell line (FZD1-10 knockout) was a gift from B. Vanhollebeke. The FZD null cell line has been authenticated at ATCC by STR profiling and tested negative for mycoplasma.</p><p>For immunofluorescence, HEK293T cells were grown on poly-L-lysine-coated glass coverslips. Cells were washed with PBS and fixed with 4% paraformaldehyde for 10 min at room temperature. To visualize endogenous TMEM79, PDI, TGN46 and EEA1, cells were permeabilized with 0.2% Triton X-100 in PBS for 5 min, blocked with 10% normal goat serum and then incubated with respective antibodies for 1 hr at room temperature followed by incubation with secondary antibodies (Alexa Fluor 594 goat anti-rabbit immunoglobulin and Alexa Fluor 488 goat anti-mouse immunoglobulin, Invitrogen). Cells were mounted in Prolong Diamond Antifade Mountant with DAPI (Thermofisher Scientific) and imaged using a Zeiss LSM700 confocal microscope.</p><p>siRNA transfection was done using Lipofectamine RNAiMAX (Thermofisher Scientific, #13778075). Duplex siRNAs targeting <italic>TMEM79</italic> and <italic>ZNRF3</italic> were purchased from Sigma-Aldrich. The sequences are as follows: <italic>TMEM79-</italic>1, 5-<named-content content-type="sequence">CAGGCGAGGGCGAGUGC</named-content> <named-content content-type="sequence">CGAAdTdT</named-content>-3, <italic>TMEM79-2, 5-</italic><named-content content-type="sequence">CCAUGAGUUCCCGCCUGAUdTdT</named-content>-3. ZNRF3, 5-<named-content content-type="sequence">CGGC UGCUACACUGAGGACUAdTdT</named-content>-3.</p><p>For Top-Flash reporter assay, Top-Flash reporter cell line (HEK293T<sup>B/R</sup>, cells harbor stably infected superTOP-Flash (BAR) and Renilla (internal control) vectors) (<xref ref-type="bibr" rid="bib6">Chen and He, 2019</xref>) or HEK293T cells transfected with Supertopflash and renilla plasmids were used. superTopflash plasmid contains multimerized WREs (Wnt-responsive elements) followed by a luciferase gene. Fopflash is a negative control luciferase reporter with mutated WREs and not Wnt-responsive. Cells were plated in 24-well plates and transfected the following day in triplicate using FuGENE HD (Promega, #E2312). Dual luciferase reporter assays were performed using Dual-Luciferase Reporter Assay System (Promega, #E1960) according to manufacturer’s instruction. Representative results are shown from one of three (or more) independent experiments.</p></sec><sec id="s4-4"><title>Immunoblotting, cell surface protein labeling and immunoprecipitation</title><p>Total cell lysates in NP40 lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40, 10% glycerol, 10 mM NaF, and protease inhibitor cocktail, pH = 7.4) were prepared by gentle rotating at 4°C, followed by centrifugation at top speed for 10 min at 4°C. Samples were run on a SDS-PAGE and transferred to Immobilon-P membrane. To isolate the cytoplasmic fraction of β-catenin, cells were incubated with 0.015% digitonin (in PBS supplemented protease inhibitor cocktail) by gentle rotating at 4°C for 10 min. Indirect immunochemistry using a secondary antibody conjugated with horseradish peroxidase was visualized using ECL reagents on LAS-4000 imager (FujiFilm).</p><p>Cell surface proteins were biotinylated using EZ-LinkSulfo-NHS-SS-Biotin (Thermo Fisher Scientific) according to manufacturer’s protocol. Biotinylated proteins were enriched by Pierce Streptavidin agarose resins.</p><p>For immunoprecipitation, transfected HEK293T cells were lysed in NP40 lysis buffer. Cell lysates were incubated with antibody conjugated Agarose beads (Pierce Anti-c-Myc Agarose, #20168; Pierce Anti-HA Agarose, #26181; Anti-Flag M2 affinity gel, Sigma-Aldrich, A2220; Anti-V5 Agarose Affinity Gel, Sigma-Aldrich, A7345) at 4°C overnight. Beads were washed with lysis buffer five times and proteins were eluted in 2x sample buffer.</p></sec><sec id="s4-5"><title>Generation of HEK293T knockout (KO) and kncokin (KI) cell lines</title><p>KO cell lines were generated using CRISPR/Cas9 according to protocols (<xref ref-type="bibr" rid="bib47">Ran et al., 2013</xref>). Briefly, HEK293T cells were transiently transfected with sgRNA plasmids containing Cas9 and selected with puromycin for 2–3 days. Monoclonal populations by limiting dilution were isolated in 96-well plate. To screen for <italic>TMEM79</italic> KO and <italic>USP8</italic> KO, sgRNA target regions were PCR amplified and characterized by Sanger sequencing. PCR products that showed multiple peaks around the target site in chromatogram were then cloned in PCR4 Blunt-TOPO (Thermo Fisher Scientific). Individual colonies were sequenced to ensure frame shift indels. To generate β-catenin-EGFP knockin cell line, HEK293T cells were transfected with donor containing EGFP and homologous arms together with sgRNAs plasmid. GFP+ cells were selected by FACS.</p></sec><sec id="s4-6"><title>Tandem affinity purification and mass spectrometry</title><p>HEK293T cells stably expressing EGFP or TMEM79-Myc-Flag were washed in cold PBS and lysed in NP40 lysis buffer. Cleared cell lysates were incubated with Anti-Flag M2 affinity gel at 4°C with gentle rotation for 4 hr. The beads were washed five times with lysis buffer. Bound proteins were eluted with the Flag peptide (N-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-C). The protein elution was then incubated with Anti-c-Myc Agarose beads overnight at 4°C. Proteins were eluted with the c-Myc peptide (N-Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-C), resolved on 4–12% NuPage gel (Thermo Fisher Scientific), and stained with The SilverQuest Silver Staining Kit (Thermo Fisher Scientific). Visible gel bands and negative control lane were sliced and sent to the Mass Spectrometry Core for analysis.</p></sec><sec id="s4-7"><title>Ubiquitylation assay</title><p>His-ubiquitin along with V5-tagged FZD5, TMEM79 and USP8 were transfected into HEK293T cells. 24 hr post transfection, cells were treated with Bafilomycin A1 (Sigma-Aldrich) overnight, washed and collected in ice-cold PBS with 10 mM N-ethyl maleimide (Sigma-Aldrich). Cells were lysed in lysis buffer containing 8 M urea, 100 mM Na<sub>2</sub>HPO4, 0.5% NP40, 10 mM Tris–HCl (pH 8.0), 10 mM imidazole and 10 mM β-mercaptoethanol. After sonication, lysates were cleared by centrifugation and incubated with nickel beads (Ni-NTA, Qiagen) for 3 hr at room temperature. Beads were washed with lysis buffer with 0.2% SDS. His-tagged proteins were eluted with 2x sample buffer and boiled at 100°C for 5 min. Eluates were then diluted 10-fold in regular lysis buffer and subjected to immunoprecipitation with Anti-V5 Agarose gel. Immunoprecipitates were resolved by SDS–PAGE and analyzed by immunoblotting assay.</p></sec><sec id="s4-8"><title><italic>Xenopus</italic> embryo manipulations</title><p>Procedures for embryo manipulation, reverse transcription PCR and in situ hybridization were performed as previously described (<xref ref-type="bibr" rid="bib64">Zhang et al., 2012</xref>). The full -ength <italic>Xenopus laevis</italic> Tmem79 cDNA was used to make in situ sense and antisense probes.</p></sec><sec id="s4-9"><title>mRNA and morpholino injection</title><p>For animal cap assays, indicated mRNAs (Tmem79, 100 and 200 pg; Xwnt8, 10 pg; β-catenin 50 pg; Xnr1, 250 pg; BMP4, 100 pg) were injected into the animal pole at 4 cell stage, and animal caps were dissected at stage 9 (in the case of Xwnt8, Xnr1, BMP4) or at stage 8.5 and treated with recombinant proteins (bFGF, 100 ng/mL; hShh, 1.5 ng/mL) until stage 10 before RT-PCR. For Neural induction assay, the MO (20 ng) for Tmem79 (Tmem79.S MO, 5’- <named-content content-type="sequence">TCTGGAGCAACCATTGGACTTCTGT</named-content> −3’ and Tmem79.L MO, 5’- <named-content content-type="sequence">TGTTTCAGGAGACACCATTGGACTT</named-content> −3’), Usp8 (Usp8 MO, 5’- <named-content content-type="sequence">GCTGCAAATTCTCCTCTCTTATCAA</named-content> −3’) or β-catenin was injected into the animal pole at 4 cell stage, and animal caps were dissected at stage nine and treated with recombinant protein Noggin (500 ng/mL) until stage 18 before RT-PCR. To examine Tmem79 and Usp8 MOs specificity, 500 pg of mRNA of <italic>Xenopus</italic> Tmem79, mouse Tmem79, <italic>Xenopus</italic> Usp8 or xmutUsp8 (<italic>Xenopus</italic> Usp8 mutated for mismatches with the MO) were injected with a control MO, Tmem79 MO or Usp8 MO (20 ng) into the animal pole at the 2 cell stage and cultured til stage 10 for Western blotting. To knockdown the endogenous xTmem79 or xUsp8, 20 ng of control MO, Tmem79 MO or Usp8 MO were injected into two dorso-animal blastomeres at the 8 cell stage and the phenotype was scored at stage 35. To rescue the Tmem79 MO phenotype, 200 pg of mTmem79, 20 ng of Usp8 MO or 10 ng of β-catenin MO was injected together with Tmem79 MO (20 ng).</p></sec><sec id="s4-10"><title>Phylogeny analysis and protein sequences</title><p>TMEM79 protein sequences were derived from full-length NCBI accessions and genomic sequences. Human (<italic>Homo sapiens</italic>): NP_115699.1, Chimpanzee (<italic>Pan troglodytes</italic>): XP_001165258.1, Rat (<italic>Rattus norvegicus</italic>): NP_001029068.1, Mouse (<italic>Mus musculus</italic>): NP_077208.1, Chicken (<italic>Gallus gallus</italic>): XP_024999333.1, Frog (<italic>Xenopus laevis</italic>): XP_018089022.1, Zebra fish (<italic>Danio rerio</italic>): XP_009290676.1, Coelacanth (<italic>Latimeria chalumnae</italic>): XP_014351966.1, Saccoglossus kowalevskii: XP_006824639.1, Helobdella robusta: XP_009026925.1, Pecten maximus, XP_033729952.1, Pocillopora damicornis: XP_027058454.1, and <italic>Nematostella vectensis</italic>: XP_032230635.1. The Protein sequences encoded by mouse MAPEG family (Membrane-Associated Proteins in Eicosanoid and Glutathione metabolism, pfam01124) members protein sequences were derived from full-length NCBI accessions and genomic sequences. Mgst1: NP_001334418, Mgst2: NP_001297411.1, Mgst3: NP_079845.1, Flap: NP_033793.1 and Ltc4s: NP_032547.1. The Protein sequences from different vertebrate species of TMEM79 were aligned using ClustalW2 multiple sequence-alignment software. The protein sequence from MAPEG superfamily members were aligned to TMEM79 using ClustalW2 multiple sequence-alignment software. Black color represents identical amino acid residues and grey color represents conservative amino acid residues. The TMEM79 evolutionary history was inferred using the Neighbor-Joining method (<xref ref-type="bibr" rid="bib51">Saitou and Nei, 1987</xref>). The optimal tree with the sum of branch length = 2.71961709 is shown. The percentages of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches (<xref ref-type="bibr" rid="bib14">Felsenstein, 1985</xref>). The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Poisson correction method (<xref ref-type="bibr" rid="bib66">Zuckerkandl and Pauling, 1965</xref>) and are in the units of the number of amino acid substitutions per site. This analysis involved eight amino acid sequences. All ambiguous positions were removed for each sequence pair (pairwise deletion option). There were a total of 534 positions in the final dataset. Evolutionary analyses were conducted in MEGA X (<xref ref-type="bibr" rid="bib26">Kumar et al., 2018</xref>). The identity between species was determined by GeneCode software.</p></sec><sec id="s4-11"><title>Quantification and statistical analysis</title><p>Un-saturated immunoblotting bands were quantified by densitometric analysis with Image J software. Error bars represent SEM from at least three independent experiments. Statistical significance was calculated by Student’s t test using GraphPad Prism and denoted as follows: *=p &lt; 0.05, **=p &lt; 0.01, ***=p &lt; 0.001, ****=p &lt; 0.0001.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank R Segal, F Cong, J-P Saint-Jeannet, and M Maurice for plasmids, B Vanhollebeke and F Cong for KO cells, D Finley, R Geha, T Schwarz, and W Wei, D Julius, L Yuan, and Y-C Hsu for discussion. NGA was in part supported by a Goldenson fellowship of Harvard Medical School. J T was in part supported by a visiting scholarship from Chinese Scholarship Council (CSC) and Central South University. J G A is supported by CNPq and Rio de Janeiro State Foundation for Science support (FAPERJ). XH acknowledges support by NIH (R01GM126120 and R35GM134953) and by Boston Children's Hospital (BCH) Pilot and Translational Research Program (TRP) grants, and BCH Intellectual and Developmental Disabilities Research Center (P30 HD-18655). XH is an American Cancer Society Research Professor.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>has filed a patent application through Boston Children's Hospital on atopic dermatitis therapeutics Patent# WO2020069344A1.</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>has filed a patent application through Boston Children's Hospital on atopic dermatitis therapeutics Patent# WO2020069344A1 and is a scientific advisory board member of Leap Therapeutics, a cancer therapeutics company.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Supervision, Validation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: All <italic>Xenopus</italic> experiments were approved by Boston Children's Hospital (BCH) Institutional Animal Care and Use Committee (IACUC) and performed under protocol 18-09-3780R.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary File 1A.</title><p>Number of embryos examined for anterior phenotypes in <xref ref-type="fig" rid="fig6">Figure 6D</xref>. Supplementary File 1B. Number of embryos examined for pigmentation phenotype in <xref ref-type="fig" rid="fig6">Figure 6D</xref>. Supplementary File 1C. Number of embryos examined for neural versus epidermal marker expression in <xref ref-type="fig" rid="fig6">Figure 6F</xref>. Supplementary File 1D. Number of embryos examined for spina bifida in <xref ref-type="fig" rid="fig7">Figure 7B</xref>. Supplementary File 1E. Number of embryos examined for axial elongation defect in <xref ref-type="fig" rid="fig7">Figure 7D</xref>. Supplementary File 1F. Number of animal pole explants examined for axial mesoderm elongation in <xref ref-type="fig" rid="fig7">Figure 7F</xref>. Supplementary File 1G. Number of embryos examined for enlarged head or spina bifida in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>. Supplementary File 1H. Number of embryos examined for anterior marker expression in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>. Supplementary File 1I. Number of embryos examined for anterior phenotypes in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>. Supplementary File 1J. Number of embryos examined for dorsal/organizer marker expression in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>. Supplementary File 1K. Number of embryos examined for neural crest marker expression in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1H</xref>.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-56793-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-56793-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All datasets associated with this article are available. Source data were uploaded. Raw data for <italic>Xenopus</italic> are in the Supplementary file 1.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Amado</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Reis</surname><given-names>A</given-names></name><name><surname>Ge</surname><given-names>M</given-names></name><name><surname>Abreu</surname><given-names>JG</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>MEM79/MATTRIN defines a pathway for Frizzled regulation and is required for Xenopus embryogenesis</data-title><source>Mendeley Data</source><pub-id assigning-authority="other" pub-id-type="doi">10.17632/2v5jg2zksj.1</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alwan</surname> <given-names>HA</given-names></name><name><surname>van Leeuwen</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation</article-title><source>Journal of Biological Chemistry</source><volume>282</volume><fpage>1658</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1074/jbc.M604711200</pub-id><pub-id pub-id-type="pmid">17121848</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustin</surname> <given-names>I</given-names></name><name><surname>Gross</surname> <given-names>J</given-names></name><name><surname>Baumann</surname> <given-names>D</given-names></name><name><surname>Korn</surname> <given-names>C</given-names></name><name><surname>Kerr</surname> <given-names>G</given-names></name><name><surname>Grigoryan</surname> <given-names>T</given-names></name><name><surname>Mauch</surname> <given-names>C</given-names></name><name><surname>Birchmeier</surname> <given-names>W</given-names></name><name><surname>Boutros</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Loss of epidermal evi/Wls results in a phenotype resembling psoriasiform dermatitis</article-title><source>The Journal of Experimental Medicine</source><volume>210</volume><fpage>1761</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1084/jem.20121871</pub-id><pub-id pub-id-type="pmid">23918954</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname> <given-names>MT</given-names></name><name><surname>Wallingford</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Planar cell polarity in development and disease</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>18</volume><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.11</pub-id><pub-id pub-id-type="pmid">28293032</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname> <given-names>JA</given-names></name><name><surname>Kirkness</surname> <given-names>EF</given-names></name><name><surname>Simakov</surname> <given-names>O</given-names></name><name><surname>Hampson</surname> <given-names>SE</given-names></name><name><surname>Mitros</surname> <given-names>T</given-names></name><name><surname>Weinmaier</surname> <given-names>T</given-names></name><name><surname>Rattei</surname> <given-names>T</given-names></name><name><surname>Balasubramanian</surname> <given-names>PG</given-names></name><name><surname>Borman</surname> <given-names>J</given-names></name><name><surname>Busam</surname> <given-names>D</given-names></name><name><surname>Disbennett</surname> <given-names>K</given-names></name><name><surname>Pfannkoch</surname> <given-names>C</given-names></name><name><surname>Sumin</surname> <given-names>N</given-names></name><name><surname>Sutton</surname> <given-names>GG</given-names></name><name><surname>Viswanathan</surname> <given-names>LD</given-names></name><name><surname>Walenz</surname> <given-names>B</given-names></name><name><surname>Goodstein</surname> <given-names>DM</given-names></name><name><surname>Hellsten</surname> <given-names>U</given-names></name><name><surname>Kawashima</surname> <given-names>T</given-names></name><name><surname>Prochnik</surname> <given-names>SE</given-names></name><name><surname>Putnam</surname> <given-names>NH</given-names></name><name><surname>Shu</surname> <given-names>S</given-names></name><name><surname>Blumberg</surname> <given-names>B</given-names></name><name><surname>Dana</surname> <given-names>CE</given-names></name><name><surname>Gee</surname> <given-names>L</given-names></name><name><surname>Kibler</surname> <given-names>DF</given-names></name><name><surname>Law</surname> <given-names>L</given-names></name><name><surname>Lindgens</surname> <given-names>D</given-names></name><name><surname>Martinez</surname> <given-names>DE</given-names></name><name><surname>Peng</surname> <given-names>J</given-names></name><name><surname>Wigge</surname> <given-names>PA</given-names></name><name><surname>Bertulat</surname> <given-names>B</given-names></name><name><surname>Guder</surname> <given-names>C</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Ozbek</surname> <given-names>S</given-names></name><name><surname>Watanabe</surname> <given-names>H</given-names></name><name><surname>Khalturin</surname> <given-names>K</given-names></name><name><surname>Hemmrich</surname> <given-names>G</given-names></name><name><surname>Franke</surname> <given-names>A</given-names></name><name><surname>Augustin</surname> <given-names>R</given-names></name><name><surname>Fraune</surname> <given-names>S</given-names></name><name><surname>Hayakawa</surname> <given-names>E</given-names></name><name><surname>Hayakawa</surname> <given-names>S</given-names></name><name><surname>Hirose</surname> <given-names>M</given-names></name><name><surname>Hwang</surname> <given-names>JS</given-names></name><name><surname>Ikeo</surname> <given-names>K</given-names></name><name><surname>Nishimiya-Fujisawa</surname> <given-names>C</given-names></name><name><surname>Ogura</surname> <given-names>A</given-names></name><name><surname>Takahashi</surname> <given-names>T</given-names></name><name><surname>Steinmetz</surname> <given-names>PR</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Aufschnaiter</surname> <given-names>R</given-names></name><name><surname>Eder</surname> <given-names>MK</given-names></name><name><surname>Gorny</surname> <given-names>AK</given-names></name><name><surname>Salvenmoser</surname> <given-names>W</given-names></name><name><surname>Heimberg</surname> <given-names>AM</given-names></name><name><surname>Wheeler</surname> <given-names>BM</given-names></name><name><surname>Peterson</surname> <given-names>KJ</given-names></name><name><surname>Böttger</surname> <given-names>A</given-names></name><name><surname>Tischler</surname> <given-names>P</given-names></name><name><surname>Wolf</surname> <given-names>A</given-names></name><name><surname>Gojobori</surname> <given-names>T</given-names></name><name><surname>Remington</surname> <given-names>KA</given-names></name><name><surname>Strausberg</surname> <given-names>RL</given-names></name><name><surname>Venter</surname> <given-names>JC</given-names></name><name><surname>Technau</surname> <given-names>U</given-names></name><name><surname>Hobmayer</surname> <given-names>B</given-names></name><name><surname>Bosch</surname> <given-names>TC</given-names></name><name><surname>Holstein</surname> <given-names>TW</given-names></name><name><surname>Fujisawa</surname> <given-names>T</given-names></name><name><surname>Bode</surname> <given-names>HR</given-names></name><name><surname>David</surname> <given-names>CN</given-names></name><name><surname>Rokhsar</surname> <given-names>DS</given-names></name><name><surname>Steele</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The dynamic genome of Hydra</article-title><source>Nature</source><volume>464</volume><fpage>592</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/nature08830</pub-id><pub-id pub-id-type="pmid">20228792</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Dodge</surname> <given-names>ME</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Ma</surname> <given-names>Z</given-names></name><name><surname>Fan</surname> <given-names>CW</given-names></name><name><surname>Wei</surname> <given-names>S</given-names></name><name><surname>Hao</surname> <given-names>W</given-names></name><name><surname>Kilgore</surname> <given-names>J</given-names></name><name><surname>Williams</surname> <given-names>NS</given-names></name><name><surname>Roth</surname> <given-names>MG</given-names></name><name><surname>Amatruda</surname> <given-names>JF</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Lum</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and Cancer</article-title><source>Nature Chemical Biology</source><volume>5</volume><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nchembio.137</pub-id><pub-id pub-id-type="pmid">19125156</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>M</given-names></name><name><surname>He</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>APC deficiency leads to β-Catenin stabilization and signaling independent of LRP5/6</article-title><source>Developmental Cell</source><volume>49</volume><fpage>825</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.05.013</pub-id><pub-id pub-id-type="pmid">31211990</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>YS</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Ito</surname> <given-names>M</given-names></name><name><surname>Peng</surname> <given-names>T</given-names></name><name><surname>Cui</surname> <given-names>Z</given-names></name><name><surname>Nagy</surname> <given-names>A</given-names></name><name><surname>Hadjantonakis</surname> <given-names>AK</given-names></name><name><surname>Lang</surname> <given-names>RA</given-names></name><name><surname>Cotsarelis</surname> <given-names>G</given-names></name><name><surname>Andl</surname> <given-names>T</given-names></name><name><surname>Morrisey</surname> <given-names>EE</given-names></name><name><surname>Millar</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Distinct functions for wnt/β-catenin in hair follicle stem cell proliferation and survival and interfollicular epidermal homeostasis</article-title><source>Cell Stem Cell</source><volume>13</volume><fpage>720</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.10.003</pub-id><pub-id pub-id-type="pmid">24315444</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruciat</surname> <given-names>CM</given-names></name><name><surname>Niehrs</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Secreted and transmembrane wnt inhibitors and activators</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>5</volume><elocation-id>a015081</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a015081</pub-id><pub-id pub-id-type="pmid">23085770</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dainichi</surname> <given-names>T</given-names></name><name><surname>Kitoh</surname> <given-names>A</given-names></name><name><surname>Otsuka</surname> <given-names>A</given-names></name><name><surname>Nakajima</surname> <given-names>S</given-names></name><name><surname>Nomura</surname> <given-names>T</given-names></name><name><surname>Kaplan</surname> <given-names>DH</given-names></name><name><surname>Kabashima</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis</article-title><source>Nature Immunology</source><volume>19</volume><fpage>1286</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0256-2</pub-id><pub-id pub-id-type="pmid">30446754</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lau</surname> <given-names>W</given-names></name><name><surname>Peng</surname> <given-names>WC</given-names></name><name><surname>Gros</surname> <given-names>P</given-names></name><name><surname>Clevers</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The R-spondin/Lgr5/Rnf43 module: regulator of wnt signal strength</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>305</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1101/gad.235473.113</pub-id><pub-id pub-id-type="pmid">24532711</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Robertis</surname> <given-names>EM</given-names></name><name><surname>Kuroda</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Dorsal-ventral patterning and neural induction in <italic>Xenopus embryos</italic></article-title><source>Annual Review of Cell and Developmental Biology</source><volume>20</volume><fpage>285</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.20.011403.154124</pub-id><pub-id pub-id-type="pmid">15473842</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emrick</surname> <given-names>JJ</given-names></name><name><surname>Mathur</surname> <given-names>A</given-names></name><name><surname>Wei</surname> <given-names>J</given-names></name><name><surname>Gracheva</surname> <given-names>EO</given-names></name><name><surname>Gronert</surname> <given-names>K</given-names></name><name><surname>Rosenblum</surname> <given-names>MD</given-names></name><name><surname>Julius</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tissue-specific contributions of <italic>Tmem79</italic> to atopic dermatitis and mast cell-mediated histaminergic itch</article-title><source>PNAS</source><volume>115</volume><fpage>E12091</fpage><lpage>E12100</lpage><pub-id pub-id-type="doi">10.1073/pnas.1814132115</pub-id><pub-id pub-id-type="pmid">30463955</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eubelen</surname> <given-names>M</given-names></name><name><surname>Bostaille</surname> <given-names>N</given-names></name><name><surname>Cabochette</surname> <given-names>P</given-names></name><name><surname>Gauquier</surname> <given-names>A</given-names></name><name><surname>Tebabi</surname> <given-names>P</given-names></name><name><surname>Dumitru</surname> <given-names>AC</given-names></name><name><surname>Koehler</surname> <given-names>M</given-names></name><name><surname>Gut</surname> <given-names>P</given-names></name><name><surname>Alsteens</surname> <given-names>D</given-names></name><name><surname>Stainier</surname> <given-names>DYR</given-names></name><name><surname>Garcia-Pino</surname> <given-names>A</given-names></name><name><surname>Vanhollebeke</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A molecular mechanism for wnt ligand-specific signaling</article-title><source>Science</source><volume>361</volume><elocation-id>eaat1178</elocation-id><pub-id pub-id-type="doi">10.1126/science.aat1178</pub-id><pub-id pub-id-type="pmid">30026314</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felsenstein</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Confidence limits on phylogenies: an approach using the bootstrap</article-title><source>Evolution</source><volume>39</volume><fpage>783</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1111/j.1558-5646.1985.tb00420.x</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Epithelial skin biology: three decades of developmental biology, a hundred questions answered and a thousand new ones to address</article-title><source>Current Topics in Developmental Biology</source><volume>116</volume><fpage>357</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1016/bs.ctdb.2015.11.033</pub-id><pub-id pub-id-type="pmid">26970628</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gammons</surname> <given-names>M</given-names></name><name><surname>Bienz</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Multiprotein complexes governing wnt signal transduction</article-title><source>Current Opinion in Cell Biology</source><volume>51</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2017.10.008</pub-id><pub-id pub-id-type="pmid">29153704</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glinka</surname> <given-names>A</given-names></name><name><surname>Wu</surname> <given-names>W</given-names></name><name><surname>Delius</surname> <given-names>H</given-names></name><name><surname>Monaghan</surname> <given-names>AP</given-names></name><name><surname>Blumenstock</surname> <given-names>C</given-names></name><name><surname>Niehrs</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction</article-title><source>Nature</source><volume>391</volume><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/34848</pub-id><pub-id pub-id-type="pmid">9450748</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname> <given-names>HX</given-names></name><name><surname>Xie</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Charlat</surname> <given-names>O</given-names></name><name><surname>Oster</surname> <given-names>E</given-names></name><name><surname>Avello</surname> <given-names>M</given-names></name><name><surname>Lei</surname> <given-names>H</given-names></name><name><surname>Mickanin</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>D</given-names></name><name><surname>Ruffner</surname> <given-names>H</given-names></name><name><surname>Mao</surname> <given-names>X</given-names></name><name><surname>Ma</surname> <given-names>Q</given-names></name><name><surname>Zamponi</surname> <given-names>R</given-names></name><name><surname>Bouwmeester</surname> <given-names>T</given-names></name><name><surname>Finan</surname> <given-names>PM</given-names></name><name><surname>Kirschner</surname> <given-names>MW</given-names></name><name><surname>Porter</surname> <given-names>JA</given-names></name><name><surname>Serluca</surname> <given-names>FC</given-names></name><name><surname>Cong</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ZNRF3 promotes wnt receptor turnover in an R-spondin-sensitive manner</article-title><source>Nature</source><volume>485</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/nature11019</pub-id><pub-id pub-id-type="pmid">22575959</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname> <given-names>H-X</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Cong</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Control of wnt receptor turnover by R-spondin-ZNRF3/RNF43 signaling module and its dysregulation in Cancer</article-title><source>Cancers</source><volume>8</volume><elocation-id>54</elocation-id><pub-id pub-id-type="doi">10.3390/cancers8060054</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heasman</surname> <given-names>J</given-names></name><name><surname>Kofron</surname> <given-names>M</given-names></name><name><surname>Wylie</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Beta-catenin signaling activity dissected in the early <italic>Xenopus embryo</italic>: a novel antisense approach</article-title><source>Developmental Biology</source><volume>222</volume><fpage>124</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1006/dbio.2000.9720</pub-id><pub-id pub-id-type="pmid">10885751</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holstein</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The evolution of the wnt pathway</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a007922</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a007922</pub-id><pub-id pub-id-type="pmid">22751150</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname> <given-names>JW</given-names></name><name><surname>Schleithoff</surname> <given-names>L</given-names></name><name><surname>Bartram</surname> <given-names>CR</given-names></name><name><surname>Schulz</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>An oncogenic fusion product of the phosphatidylinositol 3-kinase p85beta subunit and HUMORF8, a putative deubiquitinating enzyme</article-title><source>Oncogene</source><volume>16</volume><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201695</pub-id><pub-id pub-id-type="pmid">9582025</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Charlat</surname> <given-names>O</given-names></name><name><surname>Zamponi</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Cong</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dishevelled promotes wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases</article-title><source>Molecular Cell</source><volume>58</volume><fpage>522</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.03.015</pub-id><pub-id pub-id-type="pmid">25891077</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Shiba-Ishii</surname> <given-names>A</given-names></name><name><surname>Nakagawa</surname> <given-names>T</given-names></name><name><surname>Husni</surname> <given-names>RE</given-names></name><name><surname>Sakashita</surname> <given-names>S</given-names></name><name><surname>Takeuchi</surname> <given-names>T</given-names></name><name><surname>Noguchi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma</article-title><source>Pathology International</source><volume>67</volume><fpage>292</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1111/pin.12546</pub-id><pub-id pub-id-type="pmid">28544031</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname> <given-names>BK</given-names></name><name><surname>Spit</surname> <given-names>M</given-names></name><name><surname>Jordens</surname> <given-names>I</given-names></name><name><surname>Low</surname> <given-names>TY</given-names></name><name><surname>Stange</surname> <given-names>DE</given-names></name><name><surname>van de Wetering</surname> <given-names>M</given-names></name><name><surname>van Es</surname> <given-names>JH</given-names></name><name><surname>Mohammed</surname> <given-names>S</given-names></name><name><surname>Heck</surname> <given-names>AJ</given-names></name><name><surname>Maurice</surname> <given-names>MM</given-names></name><name><surname>Clevers</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of wnt receptors</article-title><source>Nature</source><volume>488</volume><fpage>665</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1038/nature11308</pub-id><pub-id pub-id-type="pmid">22895187</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>S</given-names></name><name><surname>Stecher</surname> <given-names>G</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Knyaz</surname> <given-names>C</given-names></name><name><surname>Tamura</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MEGA X: molecular evolutionary genetics analysis across computing platforms</article-title><source>Molecular Biology and Evolution</source><volume>35</volume><fpage>1547</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1093/molbev/msy096</pub-id><pub-id pub-id-type="pmid">29722887</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusserow</surname> <given-names>A</given-names></name><name><surname>Pang</surname> <given-names>K</given-names></name><name><surname>Sturm</surname> <given-names>C</given-names></name><name><surname>Hrouda</surname> <given-names>M</given-names></name><name><surname>Lentfer</surname> <given-names>J</given-names></name><name><surname>Schmidt</surname> <given-names>HA</given-names></name><name><surname>Technau</surname> <given-names>U</given-names></name><name><surname>von Haeseler</surname> <given-names>A</given-names></name><name><surname>Hobmayer</surname> <given-names>B</given-names></name><name><surname>Martindale</surname> <given-names>MQ</given-names></name><name><surname>Holstein</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Unexpected complexity of the wnt gene family in a sea Anemone</article-title><source>Nature</source><volume>433</volume><fpage>156</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1038/nature03158</pub-id><pub-id pub-id-type="pmid">15650739</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leznicki</surname> <given-names>P</given-names></name><name><surname>Kulathu</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mechanisms of regulation and diversification of deubiquitylating enzyme function</article-title><source>Journal of Cell Science</source><volume>130</volume><fpage>1997</fpage><lpage>2006</lpage><pub-id pub-id-type="doi">10.1242/jcs.201855</pub-id><pub-id pub-id-type="pmid">28476940</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Xiao</surname> <given-names>T</given-names></name><name><surname>Cong</surname> <given-names>L</given-names></name><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Irizarry</surname> <given-names>RA</given-names></name><name><surname>Liu</surname> <given-names>JS</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>554</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0554-4</pub-id><pub-id pub-id-type="pmid">25476604</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>X</given-names></name><name><surname>Tan</surname> <given-names>SH</given-names></name><name><surname>Koh</surname> <given-names>WL</given-names></name><name><surname>Chau</surname> <given-names>RM</given-names></name><name><surname>Yan</surname> <given-names>KS</given-names></name><name><surname>Kuo</surname> <given-names>CJ</given-names></name><name><surname>van Amerongen</surname> <given-names>R</given-names></name><name><surname>Klein</surname> <given-names>AM</given-names></name><name><surname>Nusse</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interfollicular epidermal stem cells self-renew via autocrine wnt signaling</article-title><source>Science</source><volume>342</volume><fpage>1226</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1126/science.1239730</pub-id><pub-id pub-id-type="pmid">24311688</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>X</given-names></name><name><surname>Nusse</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Wnt signaling in skin development, homeostasis, and disease</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>5</volume><elocation-id>a008029</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a008029</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>ZY</given-names></name><name><surname>Song</surname> <given-names>ZJ</given-names></name><name><surname>Chen</surname> <given-names>JH</given-names></name><name><surname>Wang</surname> <given-names>YF</given-names></name><name><surname>Li</surname> <given-names>SQ</given-names></name><name><surname>Zhou</surname> <given-names>LF</given-names></name><name><surname>Mao</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>YM</given-names></name><name><surname>Hu</surname> <given-names>RG</given-names></name><name><surname>Zhang</surname> <given-names>ZY</given-names></name><name><surname>Ye</surname> <given-names>HY</given-names></name><name><surname>Shen</surname> <given-names>M</given-names></name><name><surname>Shou</surname> <given-names>XF</given-names></name><name><surname>Li</surname> <given-names>ZQ</given-names></name><name><surname>Peng</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>QZ</given-names></name><name><surname>Zhou</surname> <given-names>DZ</given-names></name><name><surname>Qin</surname> <given-names>XL</given-names></name><name><surname>Ji</surname> <given-names>J</given-names></name><name><surname>Zheng</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Geng</surname> <given-names>DY</given-names></name><name><surname>Tang</surname> <given-names>WJ</given-names></name><name><surname>Fu</surname> <given-names>CW</given-names></name><name><surname>Shi</surname> <given-names>ZF</given-names></name><name><surname>Zhang</surname> <given-names>YC</given-names></name><name><surname>Ye</surname> <given-names>Z</given-names></name><name><surname>He</surname> <given-names>WQ</given-names></name><name><surname>Zhang</surname> <given-names>QL</given-names></name><name><surname>Tang</surname> <given-names>QS</given-names></name><name><surname>Xie</surname> <given-names>R</given-names></name><name><surname>Shen</surname> <given-names>JW</given-names></name><name><surname>Wen</surname> <given-names>ZJ</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Qiu</surname> <given-names>HJ</given-names></name><name><surname>Qiao</surname> <given-names>ND</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Pan</surname> <given-names>L</given-names></name><name><surname>Bao</surname> <given-names>WM</given-names></name><name><surname>Liu</surname> <given-names>YC</given-names></name><name><surname>Huang</surname> <given-names>CX</given-names></name><name><surname>Shi</surname> <given-names>YY</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Recurrent gain-of-function USP8 mutations in Cushing's disease</article-title><source>Cell Research</source><volume>25</volume><fpage>306</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.20</pub-id><pub-id pub-id-type="pmid">25675982</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname> <given-names>BT</given-names></name><name><surname>Tamai</surname> <given-names>K</given-names></name><name><surname>He</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Wnt/beta-catenin signaling: components, mechanisms, and diseases</article-title><source>Developmental Cell</source><volume>17</volume><fpage>9</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.06.016</pub-id><pub-id pub-id-type="pmid">19619488</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname> <given-names>BT</given-names></name><name><surname>He</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Frizzled and LRP5/6 receptors for wnt/β-catenin signaling</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a007880</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a007880</pub-id><pub-id pub-id-type="pmid">23209147</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matus</surname> <given-names>DQ</given-names></name><name><surname>Magie</surname> <given-names>CR</given-names></name><name><surname>Pang</surname> <given-names>K</given-names></name><name><surname>Martindale</surname> <given-names>MQ</given-names></name><name><surname>Thomsen</surname> <given-names>GH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The hedgehog gene family of the cnidarian, <italic>Nematostella vectensis</italic>, and implications for understanding metazoan hedgehog pathway evolution</article-title><source>Developmental Biology</source><volume>313</volume><fpage>501</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2007.09.032</pub-id><pub-id pub-id-type="pmid">18068698</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname> <given-names>WH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Filaggrin failure - from ichthyosis vulgaris to atopic eczema and beyond</article-title><source>British Journal of Dermatology</source><volume>175</volume><fpage>4</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/bjd.14997</pub-id><pub-id pub-id-type="pmid">27667308</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname> <given-names>E</given-names></name><name><surname>Iura</surname> <given-names>T</given-names></name><name><surname>Mukai</surname> <given-names>A</given-names></name><name><surname>Yoshimori</surname> <given-names>T</given-names></name><name><surname>Kitamura</surname> <given-names>N</given-names></name><name><surname>Komada</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes</article-title><source>Molecular Biology of the Cell</source><volume>16</volume><fpage>5163</fpage><lpage>5174</lpage><pub-id pub-id-type="doi">10.1091/mbc.e05-06-0560</pub-id><pub-id pub-id-type="pmid">16120644</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname> <given-names>Z</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Chang</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular biology of atopic dermatitis</article-title><source>Clinical Reviews in Allergy &amp; Immunology</source><volume>47</volume><fpage>193</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1007/s12016-014-8415-1</pub-id><pub-id pub-id-type="pmid">24715253</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukai</surname> <given-names>A</given-names></name><name><surname>Yamamoto-Hino</surname> <given-names>M</given-names></name><name><surname>Awano</surname> <given-names>W</given-names></name><name><surname>Watanabe</surname> <given-names>W</given-names></name><name><surname>Komada</surname> <given-names>M</given-names></name><name><surname>Goto</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Balanced ubiquitylation and deubiquitylation of frizzled regulate cellular responsiveness to wg/Wnt</article-title><source>The EMBO Journal</source><volume>29</volume><fpage>2114</fpage><lpage>2125</lpage><pub-id pub-id-type="doi">10.1038/emboj.2010.100</pub-id><pub-id pub-id-type="pmid">20495530</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niehrs</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Regionally specific induction by the Spemann-Mangold organizer</article-title><source>Nature Reviews Genetics</source><volume>5</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1038/nrg1347</pub-id><pub-id pub-id-type="pmid">15153995</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niendorf</surname> <given-names>S</given-names></name><name><surname>Oksche</surname> <given-names>A</given-names></name><name><surname>Kisser</surname> <given-names>A</given-names></name><name><surname>Löhler</surname> <given-names>J</given-names></name><name><surname>Prinz</surname> <given-names>M</given-names></name><name><surname>Schorle</surname> <given-names>H</given-names></name><name><surname>Feller</surname> <given-names>S</given-names></name><name><surname>Lewitzky</surname> <given-names>M</given-names></name><name><surname>Horak</surname> <given-names>I</given-names></name><name><surname>Knobeloch</surname> <given-names>K-P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Essential Role of Ubiquitin-Specific Protease 8 for Receptor Tyrosine Kinase Stability and Endocytic Trafficking In Vivo</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>5029</fpage><lpage>5039</lpage><pub-id pub-id-type="doi">10.1128/MCB.01566-06</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname> <given-names>R</given-names></name><name><surname>Clevers</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities</article-title><source>Cell</source><volume>169</volume><fpage>985</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyoshi</surname> <given-names>MK</given-names></name><name><surname>He</surname> <given-names>R</given-names></name><name><surname>Kumar</surname> <given-names>L</given-names></name><name><surname>Yoon</surname> <given-names>J</given-names></name><name><surname>Geha</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cellular and molecular mechanisms in atopic dermatitis</article-title><source>Advances in Immunology</source><volume>102</volume><fpage>135</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/S0065-2776(09)01203-6</pub-id><pub-id pub-id-type="pmid">19477321</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>G</given-names></name><name><surname>Suo</surname> <given-names>S</given-names></name><name><surname>Cui</surname> <given-names>G</given-names></name><name><surname>Yu</surname> <given-names>F</given-names></name><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>G</given-names></name><name><surname>Qian</surname> <given-names>Y</given-names></name><name><surname>Tam</surname> <given-names>PPL</given-names></name><name><surname>Han</surname> <given-names>J-DJ</given-names></name><name><surname>Jing</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Molecular architecture of lineage allocation and tissue organization in early mouse embryo</article-title><source>Nature</source><volume>572</volume><fpage>528</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1469-8</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrody</surname> <given-names>E</given-names></name><name><surname>Abrami</surname> <given-names>L</given-names></name><name><surname>Feldman</surname> <given-names>M</given-names></name><name><surname>Kunz</surname> <given-names>B</given-names></name><name><surname>Urbé</surname> <given-names>S</given-names></name><name><surname>van der Goot</surname> <given-names>FG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ubiquitin-dependent folding of the wnt signaling coreceptor LRP6</article-title><source>eLife</source><volume>5</volume><elocation-id>e19083</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.19083</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname> <given-names>CP</given-names></name><name><surname>Reddien</surname> <given-names>PW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Wnt signaling and the polarity of the primary body Axis</article-title><source>Cell</source><volume>139</volume><fpage>1056</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.11.035</pub-id><pub-id pub-id-type="pmid">20005801</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wright</surname> <given-names>J</given-names></name><name><surname>Agarwala</surname> <given-names>V</given-names></name><name><surname>Scott</surname> <given-names>DA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome engineering using the CRISPR-Cas9 system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reincke</surname> <given-names>M</given-names></name><name><surname>Sbiera</surname> <given-names>S</given-names></name><name><surname>Hayakawa</surname> <given-names>A</given-names></name><name><surname>Theodoropoulou</surname> <given-names>M</given-names></name><name><surname>Osswald</surname> <given-names>A</given-names></name><name><surname>Beuschlein</surname> <given-names>F</given-names></name><name><surname>Meitinger</surname> <given-names>T</given-names></name><name><surname>Mizuno-Yamasaki</surname> <given-names>E</given-names></name><name><surname>Kawaguchi</surname> <given-names>K</given-names></name><name><surname>Saeki</surname> <given-names>Y</given-names></name><name><surname>Tanaka</surname> <given-names>K</given-names></name><name><surname>Wieland</surname> <given-names>T</given-names></name><name><surname>Graf</surname> <given-names>E</given-names></name><name><surname>Saeger</surname> <given-names>W</given-names></name><name><surname>Ronchi</surname> <given-names>CL</given-names></name><name><surname>Allolio</surname> <given-names>B</given-names></name><name><surname>Buchfelder</surname> <given-names>M</given-names></name><name><surname>Strom</surname> <given-names>TM</given-names></name><name><surname>Fassnacht</surname> <given-names>M</given-names></name><name><surname>Komada</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutations in the deubiquitinase gene USP8 cause Cushing's disease</article-title><source>Nature Genetics</source><volume>47</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/ng.3166</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname> <given-names>A</given-names></name><name><surname>Kontarakis</surname> <given-names>Z</given-names></name><name><surname>Gerri</surname> <given-names>C</given-names></name><name><surname>Nolte</surname> <given-names>H</given-names></name><name><surname>Hölper</surname> <given-names>S</given-names></name><name><surname>Krüger</surname> <given-names>M</given-names></name><name><surname>Stainier</surname> <given-names>DYR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic compensation induced by deleterious mutations but not gene knockdowns</article-title><source>Nature</source><volume>524</volume><fpage>230</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/nature14580</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Row</surname> <given-names>PE</given-names></name><name><surname>Prior</surname> <given-names>IA</given-names></name><name><surname>McCullough</surname> <given-names>J</given-names></name><name><surname>Clague</surname> <given-names>MJ</given-names></name><name><surname>Urbé</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation</article-title><source>Journal of Biological Chemistry</source><volume>281</volume><fpage>12618</fpage><lpage>12624</lpage><pub-id pub-id-type="doi">10.1074/jbc.M512615200</pub-id><pub-id pub-id-type="pmid">16520378</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saitou</surname> <given-names>N</given-names></name><name><surname>Nei</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>The neighbor-joining method: a new method for reconstructing phylogenetic trees</article-title><source>Molecular Biology and Evolution</source><volume>4</volume><fpage>406</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.molbev.a040454</pub-id><pub-id pub-id-type="pmid">3447015</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Shalem</surname> <given-names>O</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved vectors and genome-wide libraries for CRISPR screening</article-title><source>Nature Methods</source><volume>11</volume><fpage>783</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3047</pub-id><pub-id pub-id-type="pmid">25075903</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname> <given-names>T</given-names></name><name><surname>Shiohama</surname> <given-names>A</given-names></name><name><surname>Kubo</surname> <given-names>A</given-names></name><name><surname>Kawasaki</surname> <given-names>H</given-names></name><name><surname>Ishida-Yamamoto</surname> <given-names>A</given-names></name><name><surname>Yamada</surname> <given-names>T</given-names></name><name><surname>Hachiya</surname> <given-names>T</given-names></name><name><surname>Shimizu</surname> <given-names>A</given-names></name><name><surname>Okano</surname> <given-names>H</given-names></name><name><surname>Kudoh</surname> <given-names>J</given-names></name><name><surname>Amagai</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A homozygous nonsense mutation in the gene for Tmem79, a component for the lamellar granule secretory system, produces spontaneous eczema in an experimental model of atopic dermatitis</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>132</volume><fpage>1111</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.08.027</pub-id><pub-id pub-id-type="pmid">24060273</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname> <given-names>SP</given-names></name><name><surname>Goh</surname> <given-names>CS</given-names></name><name><surname>Brown</surname> <given-names>SJ</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Porter</surname> <given-names>RM</given-names></name><name><surname>Cole</surname> <given-names>C</given-names></name><name><surname>Campbell</surname> <given-names>LE</given-names></name><name><surname>Gierlinski</surname> <given-names>M</given-names></name><name><surname>Barton</surname> <given-names>GJ</given-names></name><name><surname>Schneider</surname> <given-names>G</given-names></name><name><surname>Balmain</surname> <given-names>A</given-names></name><name><surname>Prescott</surname> <given-names>AR</given-names></name><name><surname>Weidinger</surname> <given-names>S</given-names></name><name><surname>Baurecht</surname> <given-names>H</given-names></name><name><surname>Kabesch</surname> <given-names>M</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Lee</surname> <given-names>YA</given-names></name><name><surname>Tavendale</surname> <given-names>R</given-names></name><name><surname>Mukhopadhyay</surname> <given-names>S</given-names></name><name><surname>Turner</surname> <given-names>SW</given-names></name><name><surname>Madhok</surname> <given-names>VB</given-names></name><name><surname>Sullivan</surname> <given-names>FM</given-names></name><name><surname>Relton</surname> <given-names>C</given-names></name><name><surname>Burn</surname> <given-names>J</given-names></name><name><surname>Meggitt</surname> <given-names>S</given-names></name><name><surname>Smith</surname> <given-names>CH</given-names></name><name><surname>Allen</surname> <given-names>MA</given-names></name><name><surname>Barker</surname> <given-names>JN</given-names></name><name><surname>Reynolds</surname> <given-names>NJ</given-names></name><name><surname>Cordell</surname> <given-names>HJ</given-names></name><name><surname>Irvine</surname> <given-names>AD</given-names></name><name><surname>McLean</surname> <given-names>WH</given-names></name><name><surname>Sandilands</surname> <given-names>A</given-names></name><name><surname>Fallon</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>132</volume><fpage>1121</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.08.046</pub-id><pub-id pub-id-type="pmid">24084074</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spemann</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1938">1938</year><source>Embryonic Development and Induction</source><publisher-loc>New Haven, Conn</publisher-loc><publisher-name>Yale University Press</publisher-name></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Neural induction: old problem, new findings, yet more questions</article-title><source>Development</source><volume>132</volume><fpage>2007</fpage><lpage>2021</lpage><pub-id pub-id-type="doi">10.1242/dev.01794</pub-id><pub-id pub-id-type="pmid">15829523</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watt</surname> <given-names>FM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mammalian skin cell biology: at the interface between laboratory and clinic</article-title><source>Science</source><volume>346</volume><fpage>937</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1126/science.1253734</pub-id><pub-id pub-id-type="pmid">25414300</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidinger</surname> <given-names>S</given-names></name><name><surname>Novak</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Atopic dermatitis</article-title><source>The Lancet</source><volume>387</volume><fpage>1109</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00149-X</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willert</surname> <given-names>K</given-names></name><name><surname>Nusse</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Wnt proteins</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a007864</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a007864</pub-id><pub-id pub-id-type="pmid">22952392</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname> <given-names>R</given-names></name><name><surname>Jia</surname> <given-names>H</given-names></name><name><surname>Fan</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Jia</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>USP8 promotes smoothened signaling by preventing its ubiquitination and changing its subcellular localization</article-title><source>PLOS Biology</source><volume>10</volume><elocation-id>e1001238</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001238</pub-id><pub-id pub-id-type="pmid">22253573</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname> <given-names>A</given-names></name><name><surname>Nagano</surname> <given-names>T</given-names></name><name><surname>Takehara</surname> <given-names>S</given-names></name><name><surname>Hibi</surname> <given-names>M</given-names></name><name><surname>Aizawa</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Shisa promotes head formation through the inhibition of receptor protein maturation for the caudalizing factors, wnt and FGF</article-title><source>Cell</source><volume>120</volume><fpage>223</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.11.051</pub-id><pub-id pub-id-type="pmid">15680328</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>M</given-names></name><name><surname>Zhao</surname> <given-names>C</given-names></name><name><surname>Wei</surname> <given-names>N</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Cui</surname> <given-names>J</given-names></name><name><surname>Xing</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High expression of Ubiquitin-Specific protease 8 (USP8) Is associated with poor prognosis in patients with cervical squamous cell carcinoma</article-title><source>Medical Science Monitor</source><volume>24</volume><fpage>4934</fpage><lpage>4943</lpage><pub-id pub-id-type="doi">10.12659/MSM.909235</pub-id><pub-id pub-id-type="pmid">30010158</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Mlodzik</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Wnt-Frizzled/planar cell polarity signaling: cellular orientation by facing the wind (Wnt)</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>31</volume><fpage>623</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-100814-125315</pub-id><pub-id pub-id-type="pmid">26566118</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Abreu</surname> <given-names>JG</given-names></name><name><surname>Yokota</surname> <given-names>C</given-names></name><name><surname>MacDonald</surname> <given-names>BT</given-names></name><name><surname>Singh</surname> <given-names>S</given-names></name><name><surname>Coburn</surname> <given-names>KL</given-names></name><name><surname>Cheong</surname> <given-names>SM</given-names></name><name><surname>Zhang</surname> <given-names>MM</given-names></name><name><surname>Ye</surname> <given-names>QZ</given-names></name><name><surname>Hang</surname> <given-names>HC</given-names></name><name><surname>Steen</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Tiki1 is required for head formation via wnt cleavage-oxidation and inactivation</article-title><source>Cell</source><volume>149</volume><fpage>1565</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.04.039</pub-id><pub-id pub-id-type="pmid">22726442</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Cheong</surname> <given-names>SM</given-names></name><name><surname>Amado</surname> <given-names>NG</given-names></name><name><surname>Reis</surname> <given-names>AH</given-names></name><name><surname>MacDonald</surname> <given-names>BT</given-names></name><name><surname>Zebisch</surname> <given-names>M</given-names></name><name><surname>Jones</surname> <given-names>EY</given-names></name><name><surname>Abreu</surname> <given-names>JG</given-names></name><name><surname>He</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Notum is required for neural and head induction via wnt deacylation, oxidation, and inactivation</article-title><source>Developmental Cell</source><volume>32</volume><fpage>719</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.02.014</pub-id><pub-id pub-id-type="pmid">25771893</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zuckerkandl</surname> <given-names>E</given-names></name><name><surname>Pauling</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1965">1965</year><source>Evolutionary Divergence and Convergence in Proteins</source><publisher-loc>New York</publisher-loc><publisher-name>Academic Press</publisher-name><pub-id pub-id-type="doi">10.1016/B978-1-4832-2734-4.50017-6</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><boxed-text><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) or resource</th><th>Designation</th><th>Source or <break/>reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Gene (<italic>M. musculus</italic>)</td><td valign="top">Tmem79</td><td valign="top">Origene</td><td valign="top">MR206106</td><td/></tr><tr><td>Strain, strain background (<italic>Escherichia coli</italic>)</td><td valign="top"><italic>E. coli NEB 5-alpha</italic></td><td valign="top">New England Biolabs (NEB)</td><td valign="top">Cat#C2987H</td><td/></tr><tr><td>Strain, strain background (<italic>Xenopus laevis</italic>)</td><td valign="top"><italic>Xenopus laevis</italic></td><td valign="top">Nasco</td><td valign="top">Cat# LM00715</td><td/></tr><tr><td>Strain, strain background (<italic>Xenopus laevis</italic>)</td><td valign="top"><italic>Xenopus laevis</italic></td><td valign="top">Nasco</td><td valign="top">Cat# LM00535</td><td/></tr><tr><td>Cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">Human: HEK293T</td><td valign="top">ATCC</td><td valign="top">Cat# CRL-11268 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_1926">CVCL_1926</ext-link></td><td/></tr><tr><td>Cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">Human: HEK293T-BAR/Renilla</td><td valign="top">He lab</td><td valign="top"/><td>See ‘dual luciferase assay’</td></tr><tr><td>Cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">Human: HEK293T-ZRKO</td><td valign="top">Feng Cong PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25891077/">25891077</ext-link></td><td valign="top"/><td/></tr><tr><td>Cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">Human: FZD null HEK293T</td><td valign="top">Benoit Vanhollebeke <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/30026314/">30026314</ext-link></td><td valign="top"/><td/></tr><tr><td>Cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">Human: HEK293T-β-catenin-EGFP knockin</td><td valign="top">This paper</td><td valign="top"/><td>He Lab; See‘Generation of HEK293T knockout (KO) and kncokin (KI) cell lines’</td></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">siRNA to TMEM79</td><td valign="top">Sigma-Aldrich</td><td valign="top"/><td valign="top">See ‘RNA interference’</td></tr><tr><td>Antibody</td><td valign="top">β-catenin <break/>(Mouse monoclonal)</td><td valign="top">BD Transduction Laboratories</td><td valign="top">Cat# 610154 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_397555">AB_397555</ext-link></td><td>WB (1:2000)</td></tr><tr><td>Antibody</td><td valign="top">β-tubulin <break/>(Mouse monoclonal)</td><td valign="top">Hybridoma Bank</td><td valign="top">E7</td><td>WB (1:5000)</td></tr><tr><td>Antibody</td><td valign="top">GAPDH <break/>(Rabbit monoclonal)</td><td valign="top">Cell Signaling Technology (CST)</td><td valign="top">Cat# 2118</td><td>WB (1:5000)</td></tr><tr><td>Antibody</td><td valign="top">HA tag <break/>(Rabbit monoclonal)</td><td valign="top">CST</td><td valign="top">Cat# 3724</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="top">Flag tag <break/>(Rabbit monoclonal)</td><td valign="top">CST</td><td valign="top">Cat# 14793</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="top">V5 tag <break/>(Rabbit monoclonal)</td><td valign="top">CST</td><td valign="top">Cat# 13202</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="top">LRP6 <break/>(Rabbit monoclonal)</td><td valign="top">CST</td><td valign="top">Cat# 3395</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="top">phospho-LRP6 (Ser1490) <break/>(Rabbit Polyclonal)</td><td valign="top">CST</td><td valign="top">Cat# 2568</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="top">DVL2 <break/>(Rabbit monoclonal)</td><td valign="top">CST</td><td valign="top">Cat# 3224</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="top">USP8 <break/>(Rabbit Polyclonal)</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# PA5-27947</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="top">EGFP <break/>(Mouse monoclonal)</td><td valign="top">Clontech</td><td valign="top">Cat# 632569</td><td>WB (1:1000)</td></tr><tr><td>Antibody</td><td valign="top">TMEM79 <break/>(Rabbit Polyclonal)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# SAB1305998</td><td>IF (1:200)</td></tr><tr><td>Antibody</td><td valign="top">TGN46 <break/>(Mouse monoclonal)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# SAB4200235</td><td>IF (1:200)</td></tr><tr><td>Antibody</td><td valign="top">Lamp1 <break/>(Mouse monoclonal)</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-20011</td><td>IF (1:500)</td></tr><tr><td>Antibody</td><td valign="top">EEA1 <break/>(Mouse monoclonal)</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-365652</td><td>IF (1:500)</td></tr><tr><td>Antibody</td><td valign="top">PDI <break/>(Mouse monoclonal)</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# MA3-019</td><td>IF (1:200)</td></tr><tr><td>Antibody</td><td valign="top">Anti-Calreticulin antibody <break/>(Mouse monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab22683</td><td>IF (1:200)</td></tr><tr><td>Antibody</td><td valign="top">Alexa Fluor 488 (Goat Polyclonal)</td><td valign="top">Invitrogen</td><td valign="top">Cat# A-11001</td><td>IF (1:500)</td></tr><tr><td>Antibody</td><td valign="top">Alexa Fluor 594 (Goat Polyclonal)</td><td valign="top">Invitrogen</td><td valign="top">Cat# A-11037</td><td>IF (1:500)</td></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-Tmem79-Myc-Flag <break/>(plasmid)</td><td valign="top">Origene</td><td valign="top">MR206106</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-Tmem79-Myc <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top">N/A</td><td>He lab; See ‘Plasmids’</td></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-Tmem79-Flag <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top">N/A</td><td>He lab; See‘Plasmids’</td></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-V5-FZD5 <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top">N/A</td><td>He lab; See ‘Plasmids’</td></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-V5-FZD5-K0 <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top">N/A</td><td>He lab; See‘Plasmid’</td></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-2xHA-FZD1 <break/>(plasmid)</td><td valign="top">He Lab; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17400545/">17400545</ext-link></td><td valign="top">N/A</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-2xHA-FZD2 <break/>(plasmid)</td><td valign="top">He Lab; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17400545/">17400545</ext-link></td><td valign="top">N/A</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-2xHA-FZD3 <break/>(plasmid)</td><td valign="top">He Lab; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17400545/">17400545</ext-link></td><td valign="top">N/A</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-2xHA-FZD4 <break/>(plasmid)</td><td valign="top">He Lab; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17400545/">17400545</ext-link></td><td valign="top">N/A</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-2xHA -FZD5 <break/>(plasmid)</td><td valign="top">He Lab; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17400545/">17400545</ext-link></td><td valign="top">N/A</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-2xHA-FZD6 <break/>(plasmid)</td><td valign="top">He Lab; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17400545/">17400545</ext-link></td><td valign="top">N/A</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-2xHA-FZD7 <break/>(plasmid)</td><td valign="top">He Lab; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17400545/">17400545</ext-link></td><td valign="top">N/A</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-2xHA-FZD8 <break/>(plasmid)</td><td valign="top">He Lab; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17400545/">17400545</ext-link></td><td valign="top">N/A</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pRK5-FZD9 <break/>(plasmid)</td><td valign="top">Addgene</td><td valign="top">Plasmid #42261</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="top">pCS2-2xHA-FZD10 <break/>(plasmid)</td><td valign="top">He Lab; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17400545/">17400545</ext-link></td><td valign="top">N/A</td><td/></tr><tr><td>Sequence-based reagent</td><td>siRNA Universal Negative Control</td><td>Sigma-Aldrich</td><td>SIC001</td><td/></tr><tr><td>Sequence-based reagent</td><td valign="top">siRNA to TMEM79 1#</td><td valign="top">Sigma-Aldrich</td><td valign="top"/><td>See ‘RNA interference’</td></tr><tr><td>Sequence-based reagent</td><td valign="top">siRNA to TMEM79 1#</td><td valign="top">Sigma-Aldrich</td><td valign="top"/><td>See ‘RNA interference’</td></tr><tr><td>Sequence-based reagent</td><td valign="top">Tmem79.S Morpholino</td><td valign="top">Gene Tools</td><td valign="top"/><td>See ‘Morpholino injection’</td></tr><tr><td>Sequence-based reagent</td><td valign="top">Tmem79.L Morpholino</td><td valign="top">Gene Tools</td><td valign="top"/><td>See ‘Morpholino injection’</td></tr><tr><td>Sequence-based reagent</td><td valign="top">Usp8 Morpholino</td><td valign="top">Gene Tools</td><td/><td>See ‘Morpholino injection’</td></tr><tr><td>Peptide, recombinant protein</td><td valign="top">FLAG Peptide</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# F3290</td><td/></tr><tr><td>Peptide, recombinant protein</td><td valign="top">c-MYC Peptide</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# M2435</td><td/></tr><tr><td>Peptide, recombinant protein</td><td valign="top">Recombinant Human EGF</td><td valign="top">Peprotech</td><td valign="top">Cat# AF-100–15</td><td/></tr><tr><td>Peptide, recombinant protein</td><td valign="top">bFGF2</td><td valign="top">Prospecbio</td><td valign="top">Cat# CYT-218-a</td><td/></tr><tr><td>Peptide, recombinant protein</td><td valign="top">Recombinant Human SHH</td><td valign="top">Peprotech</td><td valign="top">Cat# 100–45</td><td/></tr><tr><td>Peptide, recombinant protein</td><td valign="top">Recombinant Murine Noggin</td><td valign="top">Peprotech</td><td valign="top">Cat# 250–38</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="top">Fugene HD transfection reagent</td><td valign="top">Promega</td><td valign="top">Cat# E2312</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="top">Lipofectamine RNAiMAX</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 13778075</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="top">Dual-Luciferase Reporter Assay System</td><td valign="top">Promega</td><td valign="top">Cat# E1910</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="top">RNeasy Mini Kit</td><td valign="top">Qiagen</td><td valign="top">Cat# 74106</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="top">SilverQuest Silver Staining Kit</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# LC6070</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="top">SuperScript IV Reverse Transcriptase</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 18090200</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="top">Taq DNA Polymerase, recombinant</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 10342020</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="top">DIG RNA Labeling Mix</td><td valign="top">S Sigma-Aldrich</td><td valign="top">Cat# 11277073910</td><td/></tr><tr><td>Commercial <break/>assay or kit</td><td valign="top">Zero Blunt TOPO PCR Cloning Kit</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# K2875J10</td><td/></tr><tr><td>Chemical compound, drug</td><td valign="top">CHIR-99021</td><td valign="top">Selleckchem</td><td valign="top">Cat# S1263</td><td/></tr><tr><td>Chemical compound, drug</td><td valign="top">IWP-2</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# I0536</td><td/></tr><tr><td>Chemical compound, drug</td><td valign="top">Bafilomycin A1</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# B1793</td><td/></tr><tr><td>Chemical compound, drug</td><td valign="top">MG132</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# S2619</td><td/></tr><tr><td>Chemical compound, drug</td><td valign="top">Digitonin</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# D141</td><td/></tr><tr><td>Chemical compound, drug</td><td valign="top">Sulfo-NHS-SS-Biotin</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 21328</td><td/></tr><tr><td>Software, algorithm</td><td valign="top">Fiji</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22743772/">22743772</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002285">SCR_002285</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td valign="top">Mageck</td><td valign="top"><xref ref-type="bibr" rid="bib29">Li et al., 2014</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25476604/">25476604</ext-link></td><td valign="top"/><td/></tr><tr><td>Other</td><td valign="top">ANTI-FLAG M2 Affinity Gel</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# A2220</td><td/></tr><tr><td>Other</td><td valign="top">Anti-V5 Agarose Affinity Gel</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# A7345</td><td/></tr><tr><td>Other</td><td valign="top">Anti-c-Myc Agarose Gel</td><td valign="top">Pierce</td><td valign="top">Cat# 20168</td><td/></tr><tr><td>Other</td><td valign="top">Anti-HA Agarose</td><td valign="top">Pierce</td><td valign="top">Cat# 26181</td><td/></tr><tr><td>Other</td><td valign="top">Ni-NTA Agarose</td><td valign="top">Qiagen</td><td valign="top">Cat# 30230</td><td/></tr></tbody></table></table-wrap></boxed-text></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.56793.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Nusse</surname><given-names>Roel</given-names></name><role>Reviewing Editor</role><aff><institution>Stanford University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The work describes the identification of the multi-span transmembrane protein TMEM79/MATTRIN, as an inhibitor of Wnt signaling. TMEM79 interacts with the Wnt receptor FZD during biogenesis and leads to FZD degradation. In humans, mutations in TMEM79 are associated with Atopic dermatitis, implying that aberrant Wnt/FZD signaling is a cause for this inflammatory skin disease.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;TMEM79/MATTRIN defines a novel pathway for Frizzled regulation and is required for vertebrate embryogenesis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Cynthia Wolberger as the Senior Editor The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>The reviews are included below. As you will see, the reviewers make valuable points that will improve re-submission of the manuscript. In particular, they recommend to tone down the claims you have made, screen and fix the grammar/spelling, and comment on TMEM79 homologues in distant species. Once you have addressed these items, re-submit the paper.<italic>Reviewer #1:</italic></p><p>Points of clarification:</p><p>Since <italic>eLife</italic> does not have specific word count, we encourage the authors to describe the experiments and results in more detail in the main text and figure legends. That would make it easier for readers to follow and appreciate this work. Here is one example: add more detail to the figure legend describing the his-tagged ubiquitin pull-down (Figure 5H and I) in the legend to Figure 5. Also, walk the reader through the results (i.e. reduced Ub-Fz5 level with USP8C, but increased Ub-Fz5 level with USP8C+TMEM79, etc). In the current version of the manuscript, all of the technical information is present, but the reader needs to go to the Materials and methods section to find it, and the result of this experiment requires the reader to assess the gels with minimal text guidance.</p><p>In Figure 3G, the authors show binding with Frizzleds 1-8. Did they also test Frizzleds 9 and 10 for TMEM79 binding? The authors convincingly show that TMEM79 binds preferentially to the immature form of Frizzled5. Does that observation generalize to any of the other Frizzleds? One presumes it would, since TMEM79 is enriched in the ER.</p><p>It would be useful if the authors would list the TEME79-interacting proteins from mass spectrometry as a supplementary table.</p><p>In Figure 3C, should label TMKO be T79KO?</p><p>Figure 5C. Because there is a lot more HA-USP8C than HA-USP8N, the greater amount of co-IPed TMEM79 with HA-USP8C compared to HA-USP8N is not so significant.</p><p>In Figure 5E, does the label &quot;N&quot; refer to &quot;1-200&quot; as shown in Figure 5D?</p><p>In Figure 1—figure supplement 1A, please include the sequence alignment for the full-length TEME79 proteins and indicate the predicted transmembrane domains.</p><p>In Figure 3—figure supplement 1E, are these really the correct blots? It looks like something got mixed up.</p><p><italic>Reviewer #2:</italic></p><p>Overall, the manuscript is well written and presented. However,</p><p>1) I am concerned by overstatements of the authors, such as in the title claiming &quot;TMEM79/MATTRIN defines a novel pathway for Frizzled regulation and is required for vertebrate embryogenesis&quot; which both is not fully supported by the data shown. This is not a novel pathway and at least in mouse, it is not required for embryogenesis. The authors should in general down tone the claims.</p><p>2) Figure 1C: is an atypical representation of CRISPR screens. Data underlying 1C is not found in the manuscript.</p><p>3) Figure 2: qPCR experiments should be shown to demonstrate the knock-down effect of siRNAs</p><p><italic>Reviewer #3:</italic></p><p>For the phylogeny, the absence of sequences in <italic>Drosophila</italic> or Caenorhabditis is not always informative, since both genomes are somewhat stripped down. Indeed, there are reciprocal blast hits with extensive islands of sequence similarity in the protostomes, even annotated as TMEM79, so the analysis should be redone.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.56793.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>Points of clarification:</p><p>Since eLife does not have specific word count, we encourage the authors to describe the experiments and results in more detail in the main text and figure legends. That would make it easier for readers to follow and appreciate this work. Here is one example: add more detail to the figure legend describing the his-tagged ubiquitin pull-down (Figure 5H and I) in the legend to Figure 5. Also, walk the reader through the results (i.e. reduced Ub-Fz5 level with USP8C, but increased Ub-Fz5 level with USP8C+TMEM79, etc). In the current version of the manuscript, all of the technical information is present, but the reader needs to go to the Materials and methods section to find it, and the result of this experiment requires the reader to assess the gels with minimal text guidance.</p></disp-quote><p>We have added detailed descriptions to these and other figure legends.</p><disp-quote content-type="editor-comment"><p>In Figure 3G, the authors show binding with Frizzleds 1-8. Did they also test Frizzleds 9 and 10 for TMEM79 binding? The authors convincingly show that TMEM79 binds preferentially to the immature form of Frizzled5. Does that observation generalize to any of the other Frizzleds? One presumes it would, since TMEM79 is enriched in the ER.</p></disp-quote><p>These are important points that we felt we should address experimentally, even though we were offered to address issues related to the text only based on new COVID-19 policy. Fortunately, our institution has started recently phase I lab reopening with limited capacity. We have been able to carry out a few key experiments since. We now provide new data that show TMEM79 co-IP specifically FZD9 and FZD10, but not SMO (Figure 3—figure supplement 1F). Therefore, TMEM79 binds to all ten human FZDs (*FZD1-10), but not SMO.</p><p>Based on the reviewer’s comment, we have also tried to find if other FZDs besides FZD5 exhibit distinct immature and mature forms in SDS-PAGE. It appears that most of them do not, except for FZD5 and FZD9, but to a lesser degree for FZD9 in terms of the clarity of two separable upper and lower bands. We now add new data that TMEM79 preferentially co-IPs the lower/fast-migrating band of FZD9, presumably the immature form, while reduces the level of upper/slow-migrating bands of FZD9, which probably reflects heterogeneity of FZD9 glycosylation (Figure 3—figure supplement 1H). These new data are consistent with our data derived from FZD5. I note that FZD5 has been used since 2005 as a model for studying FZD biogenesis because of its most distinct immature and mature forms readily observed by many labs. it is likely that all FZDs go through similar biogenesis processes including glycosylation, even though their electrophoretic behavior in SDS-PAGE varies due to influences by many including unknown factors such as biophysical properties of the amino acid sequence of a particular FZD.</p><disp-quote content-type="editor-comment"><p>It would be useful if the authors would list the TEME79-interacting proteins from mass spectrometry as a supplementary table.</p></disp-quote><p>The full list of TMEM79-interacting proteins from our mass spectrometry is now provided in Figure 5—figure supplement 1B. Note that we performed targeted mass spectrometry on visible bands that were excised. The list therefore is not to be viewed as a comprehensive representation of candidate TMEM79-interacting proteins.</p><disp-quote content-type="editor-comment"><p>In Figure 3C, should label TMKO be T79KO?</p></disp-quote><p>The label was changed to T79KO.</p><disp-quote content-type="editor-comment"><p>Figure 5C. Because there is a lot more HA-USP8C than HA-USP8N, the greater amount of co-IPed TMEM79 with HA-USP8C compared to HA-USP8N is not so significant.</p></disp-quote><p>The difference of IP efficiency between HA-USP8C and HA-USP8N for TMEM79 was highly reproducible in our experiments. HA-USP8C always co-IPed TMEM79 even with lower input amount. We agree that co-IP between USP8 and TMEM79 appears to be relatively weak. This is not uncommon for co-IPs between a membrane protein and a cytosolic protein for technical and other reasons.</p><disp-quote content-type="editor-comment"><p>In Figure 5E, does the label &quot;N&quot; refer to &quot;1-200&quot; as shown in Figure 5D?</p></disp-quote><p>Yes, “N” is 1-200 of TMEM79. We now only use 1-200 in the revised Figure 5.</p><disp-quote content-type="editor-comment"><p>In Figure 1—figure supplement 1A, please include the sequence alignment for the full-length TEME79 proteins and indicate the predicted transmembrane domains.</p></disp-quote><p>The predicted transmembrane domains (TM1-TM5) are now indicated in Figure 1—figure supplement 1A.</p><disp-quote content-type="editor-comment"><p>In Figure 3—figure supplement 1E, are these really the correct blots? It looks like something got mixed up.</p></disp-quote><p>We examined Figure 3—figure supplement 1E carefully. It is correct.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:Overall, the manuscript is well written and presented. However,</p><p>1) I am concerned by overstatements of the authors, such as in the title claiming &quot;TMEM79/MATTRIN defines a novel pathway for Frizzled regulation and is required for vertebrate embryogenesis&quot; which both is not fully supported by the data shown. This is not a novel pathway and at least in mouse, it is not required for embryogenesis. The authors should in general down tone the claims.</p></disp-quote><p>We have changed the title to “TMEM79/MATTRIN defines a pathway for Frizzled regulation and is required for <italic>Xenopus</italic> embryogenesis”, which we believe is more precise and should address the reviewer’s concern.</p><disp-quote content-type="editor-comment"><p>2) Figure 1C: is an atypical representation of CRISPR screens. Data underlying 1C is not found in the manuscript.</p></disp-quote><p>We presented our screen data in a way that has taken into account the number of unique sgRNAs for a particular gene and NGS reads. Multiple unique sgRNAs of the same gene increase the confidence of the hit. The raw screen Data is included in Figure 1—source data 1.</p><disp-quote content-type="editor-comment"><p>3) Figure 2: qPCR experiments should be shown to demonstrate the knock-down effect of siRNAs</p></disp-quote><p>We added qPCR data in the new Figure 2—figure supplement 1F.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>For the phylogeny, the absence of sequences in Drosophila or Caenorhabditis is not always informative, since both genomes are somewhat stripped down. Indeed, there are reciprocal blast hits with extensive islands of sequence similarity in the protostomes, even annotated as TMEM79, so the analysis should be redone.</p></disp-quote><p>We Thank the reviewer for this insightful comment/suggestion. We reperformed the phylogenic analysis as suggested, which reveals that Tmem79 is ancient and is in cnidaria and some protostome lineages (revised Figure 1—figure supplement 1). Therefore, its absence in fruit flies and nematodes likely reflects gene losses that have been commonly observed in protostomes for Wnt genes and Wnt antagonist genes.</p><p>We further performed a phylogenic analysis of the Usp8 gene given the Tmem79-Usp8 relationship we uncovered. Usp8 almost mirrors Tmem79 in this analysis (newly added Figure 9). Usp8 is found in cnidaria and some protostome lineages but shows frequent loss in protostomes. Importantly, protostomes that have preserved the Tmem79 gene also preserve the Usp8 gene, but not vice versa (such as in <italic>Drosophila</italic>, which has Usp8 but not Tmem79). This observation holds true in every protostome species we examined and seems to be consistent with our genetic and biochemical data that Tmem79 acts through inhibition of Usp8. We revised the Discussion based on these new analyses and added a new Figure 9 to illustrate these analyses, which in our view is independent from Figure 1. Therefore we decided to use Figure 9 instead of Figure 1—figure supplement 2, which would be the option if this figure where to remain in the supplement (based on our understanding of the <italic>eLife</italic> in-house style). We are open to reviewers’ and editors’ suggestion on this matter.</p></body></sub-article></article>